sessi n - American College of Rheumatology...sessi n 2 0 17 Pre-Meeting Courses: Friday, November 3...

sessi n

2 0 1 7

Pre-Meeting Courses: Friday, November 3 — Saturday, November 4, 2017Scientific Sessions: Saturday, November 4 — Wednesday, November 8, 2017Exhibits: Sunday, November 5 — Tuesday, November 7, 2017

2

FOLD BACK FOR FLOOR MAPS

6

78911

5 4 3 2 120

33313029

28

2627 25 24 23 22 21

32

Center Terrace

Pavilion Terrace

West Terrace

East Terrace

Outdoor Amphitheatre

10

SailsPavilion(closed forrenovation)

San Diego Convention CenterGround Level● Registration (Participants) —Badge Ribbons —Hotel Information —Membership Booth —Shuttle Buses —Coat & Baggage Check —Industry-Supported Symposia Information —Business Center

● Exhibit Hall—Food Court—Innovation Theaters—ACR Discovery Center (Booth #1431) • ACR/ARHP Programs & Products • CareerConnection • Foundation Booth • Simple Tasks

● First Aid

● Registration (Exhibitors)

● Poster Hall

● Foundation Donors’ Lounge

● Restaurant Reservations & Visitor Information

Mezzanine Level● Nursing Mothers’ Room

Upper Level(see Important Detour Route information*)● Prayer Room 7B (non-denominational) ● ACR O�ce ✆ (619) 525-6250—Lost & Found (Call the ACR o�ce to check the status of your lost item.)

● Help Desk—Technology Assistance

● Newsroom ✆ (619) 525-6253● Opening Lecture & Awards● Speaker Ready Room● Technology Kiosks

Hall C

LOADING DOCKS

LOADING DOCKS

FRONT DRIVEEast Lobby

PlazaWest Lobby

Halls F & GHall B1 Marriott

Marquis

Hilton Bayfront(Meet the Professor

Sessions & Workshops)

7431

2 56

7

Upper Level

LEGENDLobby / Pre-FunctionRestroomsOutdoor Areas

171918

1312

1615 14

E. Mezz.Terrace

OutdoorAmphitheatre

W. Mezz.Terrace 8

9

Downtown San Diego

*Important Detour Route■ During our meeting, the Sails Pavilion is closed for renovation. ■ To access rooms 1-11 or rooms 20-33 on either side of the Sails Pavilion, you can:—Exit and enter from the Upper Level outside doors (bay side) on either side of the Sails Pavilion Terrace.—Or, take the escalators near Ballroom 20-A or Room 5-B up or down from the Ground Level.

San Diego Bay

11

12

13

14

15 15

*Important Detour Route

10Plaza Terrace

Mezzanine Level

Ground Level1

2

3

45

67

8

910

11

12131415

2 0 1 7 A C R / A R H P A N N U A L M E E T I N G


U se the Session Tracker to record your CME/participation hours throughout the meeting. Then use the Session Tracker as a guide when you are ready to claim CME credit or participation

hours. To record your sessions, claim credit, or print a certificate, login to your account at www.rheumatology.org.

Educational TracksUse the following tracks to navigate the meeting:

Primary Tracks Secondary Tracks

Basic Science Educators

Business/Administration Fellows-in-Training

Clinical Practice Pediatrics

Clinical Science Practice Management

TechMed

State CME Designations

Ethics Pain Management Patient Safety

2017 GLOBAL LEARNING OBJECTIVES At the conclusion of the ACR/ARHP Annual Meeting, participants should be able to:

Accreditation Statement: The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement: The American College of Rheumatology designates this live educational activity for a maximum of 54.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CLAIMING CME CREDIT

You may claim your credit online at your convenience by logging into your account at www.rheumatology.org. From your account, you can also print a CME certificate, certificate of participation, or certificate of completion. For assistance during the meeting, visit the ACR Help Desk, located at the top of the escalator, opposite Ballroom 20A.

• Identify recent developments in the diagnosis and management of patients with rheumatic diseases

• Outline new technologies for the treatment of rheumatologic problems

• Describe potential challenges in the delivery of care of patients with rheumatic diseases and specify possible solutions

• Utilize new research data to improve the quality of care of patients with rheumatic diseases

• Summarize recent rheumatology research findings

2 0 1 7

sessi n

2 0 1 7

sessi n





1

How Do I Claim Credit? The AMA requires you claim credit only for time spent actively participating in educational sessions. To facilitate accurate reporting, you may login to your account at any time to record your activity and you may claim partial credit to the nearest quarter hour. If you attempt to claim credit that exceeds the maximum available AMA PRA Category 1 CreditsTM, the system will default to the maximum credit(s) available for the session or the entire meeting.

How Do I Claim Credit for Poster Sessions? CME credit is available for viewing posters from 9:00–11:00 am on Sunday, Monday, and Tuesday, when poster presenters are available to engage learners. You should claim credit commensurate with the extent of your participation in the poster sessions during this time slot, and that may be full or partial credit up to a maximum of 2.0 hours.

Certificates and Proof of Attendance Available to Attendees The following certificates can be printed by logging into your ACR account at www.rheumatology.org.

• CME Certificate—For physician attendees who would like a record and confirmation of AMA PRA Category 1 Credits™ earned, the CME certificate displays the exact number of credits claimed.

You can record and claim CME credit at any time by logging into your ACR account. Once credit has been claimed, you can also print a CME certificate at your convenience. For assistance during the meeting, visit the ACR Help Desk, located at the top of the escalator, opposite Ballroom 20A.

• Certificate of Participation—For any meeting attendee who would like proof of attendance, this certificate acknowledges attendance/participation but does not confirm CME credit earned.

• CME Transcript—For attendees who would like a detailed listing of all educational session(s) attended and credit claimed for each session.

European Physicians who would like to receive European CME Credits (ECMECs) should login to their account at www.rheumatology.org to record and claim AMA PRA Category 1 Credits™ earned at the 2017 ACR Annual Meeting. After claiming credit, print a Certificate of Completion. In accordance with the mutual recognition of credits between the American Medical Association and the UEMS-European Accreditation Council for CME, you must submit your certificate of completion to the UEMS/EACCME for conversion of credits.



2

ACR Help Desk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Top of Escalator (opposite Ballroom 20A)

ACR Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1B; Telephone: (619) 525-6250

Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D Lobby

CareerConnection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall F-G, Discovery Center, Booth 1421

Child Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Call for Location; Telephone: (619) 525-6255

Coat/Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D Lobby

Discovery Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall F-G, Booth 1421

Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F-G

First Aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Box Office G (opposite Hall G entrance)

Food Court . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F-G

Foundation Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall F-G, Discovery Center, Booth 1421

Foundation Donors’ Lounge . . . . . . . . . . . . . . . . . . . . Tides Restaurant (next to Hall A)

Hotel Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D Lobby

Industry-Supported Symposia Information . . . . . Hall D Lobby

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall F-G

Lost and Found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ACR Office (Room 1B); Call (619) 525-6250 to check status of your lost item

Membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D Lobby

Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26A; Telephone: (619) 525-6253

Nursing Mothers’ Room . . . . . . . . . . . . . . . . . . . . . . . . 12 (Mezzanine Level)

Poster Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall C

IMPORTANT LOCATIONS





3

Prayer Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 B

Registration (Participants). . . . . . . . . . . . . . . . . . . . . . Hall D Lobby

Registration (Exhibitors). . . . . . . . . . . . . . . . . . . . . . . . Hall F-G Lobby

Restaurant Reservations . . . . . . . . . . . . . . . . . . . . . . . Hall B-2 Lobby & Hall E Lobby

Ribbon Distribution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D Lobby

Shuttle Bus Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall E Lobby

Simple Tasks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall F-G, Discovery Center, Booth 1421

Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . 22

Technology Help Desk . . . . . . . . . . . . . . . . . . . . . . . . . . Opposite Ballroom 20A Lobby

Technology Kiosks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6A Lobby, Ballroom 20 B-C Lobby, Hall D Lobby, & Hall B Lobby

Visitor Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall B-2 Lobby & Hall E Lobby

Wheelchairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Order through ScootAround, Inc.; Telephone: (888) 441-7575

Special NeedsIf you require special arrangements to participate in this meeting, please contact the ACR Office (Room 1B); Telephone: (619) 525-6250.

Emergency Contact Information

Space is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder.

Printing of this publication is supported by Amgen, Inc.

PRE-MEETING COURSES & OPENING SESSION

N O V E M B E R 3 – 4 , 2 0 1 7

FRIDAY, NOVEMBER 3

Pre-Meeting Courses - $6:30 am – 6:00 pm

SATURDAY, NOVEMBER 4

Pre-Meeting Courses - $6:30 am – 4:30 pm

Opening Lecture & Awards4:30 pm – 6:15 pm

Opening Reception (Hilton Bayfront)6:30 pm – 8:00 pm

ACR/ARHP OPENING LECTURE & AWARDS

SATURDAY, NOVEMBER 44:30 pm – 6:15 pmRoom: 20 A-DTopic: Emerging and Re-Emerging Infectious Diseases: From AIDS to Zika

Anthony S. Fauci, MD, Director of National Institutes of Health NIAID will be the 2017 ACR/ARHP Annual Meeting Opening Lecturer.

Dr. Fauci has served as the director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis, and malaria as well as emerging diseases such as Ebola and Zika.

D A Y S - A T - A - G L A N C E

7

Friday, Nov. 3 Pre-Meeting Courses

$ = Session Requires Additional Registration

STARTTIME

ENDTIME

SESSION TITLEMODERATORS/SPEAKERS

CMECREDITS

TRACK SECONDARYTRACK

ROOM

6:30 AM

5:30 PM

1F001 Pre-Mtg: ACR MSUS Course for Rheumatologists – Day 1 of 2 $MODERATOR: Jay B. Higgs

SPEAKERS: Catherine Bakewell, Paul DeMarco, Amy Evangelisto, Jay Higgs, Gurjit Kaeley, Clara Lin, Midori Nishio, Johannes Roth, Jonathan Samuels, Ralf Thiele, Karina Torralba

8.25 Clinical Practice Educator, Fellows-in-

Training, Pediatrics

32 B

7:00 AM

4:00 PM

1F002 Pre-Mtg: ACR Coding Clinic: Addressing Information Security, Risk & Compliance $ MODERATORS: Antanya Chung, Melesia Tillman

SPEAKERS: Antanya Chung, Pam Vanderbilt, Melesia Tillman

6.5 Business/Administration

Patient Safety, Practice

Manager

11 A

1:00 PM

6:00 PM

1F003 Pre-Mtg: ACR BRC: Interface of Innate & Adaptive Immunity in Rheumatic Diseases: Day 1 of 2 $ SPEAKERS: Mark Shlomchik, Greg Barton, Eicke Latz, Dan Stetson, Harris Perlman, Yanick J Crow, Nan Yan, Ralph Budd

4.75 Basic Science 6 A

1:00 PM

6:00 PM

1F004 Pre-Mtg: ACR CRC – Precision Medicine in Rheumatic Diseases: Hopes & Challenges: Day 1 of 2 $SPEAKERS: Soumya Raychaudhuri, Lindsey A. Criswell, Daniel L. Kastner, Judith A. James, Robert Gentleman, Josh Stuart, Peter Nigrovic, Shamil Sunyaev, Minoli Perera, Iain B. McInnes , Peter Nigrovic, Josh Stuart, Shamil Sunyaev, Minoli Perera, Iain B. McInnes

MODERATORS: Soumya Raychaudhuri, Lindsey A. Criswell, Judith A. James, Iain B. McInnes

4.75 Clinical Science 6 D

1:00 PM

6:00 PM

1F005 Pre-Mtg: ACR MOC Annual Meeting Course – 2017 Update in Rheumatology $MODERATOR: Allan C. Gelber

SPEAKERS: Allan C. Gelber, Erika H. Noss, Carol A. Langford

4.5 Clinical Practice 20 A

For the most up-to-date content, download the 2017 ACR/ARHP Annual Meeting App from the App Store or Google Play.

STARTTIME

ENDTIME


CMECREDITS


ROOM

Saturday, Nov. 4 Pre-Meeting Courses

6:30 AM

6:00 PM

2S001 Pre-Mtg: ACR MSUS Course for Rheumatologists: Day 2 of 2 $MODERATOR: Jay B. Higgs

SPEAKERS: Catherine Bakewell, Paul DeMarco, Amy Evangelisto, Jay Higgs, Gurjit Kaeley, Clara Lin, Midori Nishio, Johannes Roth, Jonathan Samuels, Ralf Thiele, Karina Torralba

9.25 Clinical Science Educator, Fellows-in-

Training, Pediatrics

32 B

7:00 AM

4:00 PM

2S002 Pre-Mtg: ACR Review Course $MODERATORS: Philip Seo, Peter A. Valen

SPEAKERS: Fredrick M. Wigley, James T. Rosenbaum, Sharon A. Chung, Lianne S. Gensler, Carlin Senter, Paul W. Noble, Michelle Petri, Arthur Kavanaugh

6 Clinical Practice Pain Management

Hall B1

7:00 AM

4:15 PM

2S003 Pre-Mtg: ACR CRC: Precision Medicine in Rheumatic Diseases: Hopes & Challenges: Day 2 of 2 $MODERATORS: Timothy B. Niewold, Jinoos Yazdany, Marina Sirota, Iain B. McInnes, Kevin D. Deane

SPEAKERS: Rahul Satija, Will Greenleaf, Speaker to be Determined, Lindsey A. Criswell, Marina Sirota, Soumya Raychaudhuri, Chun Jimmie Ye, Kevin D. Deane, Jinoos Yazdany, Tom W.J. Huizinga, Iain B. McInnes, Jinoos Yazdany, Tom W.J. Huizinga, Kevin D. Deane, Matthew Albert, Fan Zhang, Timothy B. Niewold, Jose U. Scher


7:00 AM

4:15 PM

2S004 Pre-Mtg: ACR Practice Mgt Course: Refocus Your Practice: Innovation, Improvement, & Insights $

MODERATORS: Meredith Strozier, Melesia Tillman

SPEAKERS: Sean M. Weiss, Larry Kemp, Ryan Larosa, Uchenna Onyeachom, Bryan Hull, Bryan Hull


Practice Manager

11 A



9

Saturday, Nov. 4 Pre-Meeting Courses


STARTTIME

ENDTIME


CMECREDITS


ROOM

7:00 AM

4:15 PM

2S005 Pre-Mtg: ARHP Clinical Focus Course: SLE: Taming the Wolf: Lessons from Practice & Research $MODERATOR: Maura D. Iversen

SPEAKERS: Maura D. Iversen, Benjamin J Smith, Tracey Wright, Bonnie L. Bermas, Edward H. Yelin, Ram R. Singh, Patricia P. Katz, Donna Everix

7.25 Clinical Practice 11 B

7:00 AM

4:30 PM

2S006 Pre-Mtg: ACR BRC: Interface of Innate & Adaptive Immunity in Rheumatic Diseases: Day 2 of 2 $SPEAKERS: Ann Marshak-Rothstein, Ignacio Sanz, Mark Shlomchik, Martin Herrmann, Umesh S Deshmukh, Ellen M. Gravallese, Keith B. Elkon, Ian Rifkin, Anne Davidson, Carla V. Rothlin, Tanya Mayadas

7 Basic Science 6 A

4:30 PM

6:15 PM

2S007 ACR/ARHP: Opening Lecture & Awards: Emerging & Re-Emerging ID: From AIDS to ZikaMODERATORS: Afton L. Hassett, Sharad Lakhanpal

SPEAKERS: Anthony Fauci

0.75 Clinical Science Ethics, Fellows-in-

Training, Pain Management, Patient Safety

20 A-D

6:30 PM

8:00 PM

2S008 Networking: Opening Reception 0 Hilton – Sapphire

Ballrooms

Corporate Roundtable

The Rheumatology Research Foundation is making great

strides in its mission to advance research and training and improve the health of people with rheumatic diseases by increasing funding for research and training, thanks in large part to the generosity of the Corporate Roundtable. Participation in the Corporate Roundtable is a direct investment in the Foundation’s efforts to develop the next generation of rheumatology professionals who will provide high-quality care for patients, as well as accelerate research that will lead to advances in treatments and, one day, cures.

leadership

principal

partner

pinnacle

executive

GlaxoSmithKline

SUNDAYN O V E M B E R 5 , 2 0 1 7

ACR/ARHP Annual Meeting First-Timers Orientation7:30 am – 8:30 am

Scientific Sessions7:30 am – 6:00 pm

Meet the Professor Sessions (Hilton Bayfront) - $7:45 am – 9:15 am12:45 pm – 2:15 pm4:30 pm – 6:00 pm

Workshops (Hilton Bayfront) - $7:45 am – 9:45 am10:30 am – 12:30 pm1:15 pm – 3:15 pm4:00 pm – 6:00 pm

Poster Session A and Poster Tours9:00 am – 11:00 am

Poster Hall Hours8:30 am – 4:00 pm

Exhibit Hall10:00 am – 5:00 pm

Innovation Theater A10:30 am – 11:15 am12:30 pm – 1:15 pm2:30 pm – 3:15 pm

Innovation Theater B11:30 am – 12:15 pm1:30 pm – 2:15 pm3:30 pm – 4:15 pm

ACR Plenary Session I11:00 am – 12:30 pm

ARHP Discipline Round Tables: Networking Forum (Hilton Bayfront)12:30 pm – 2:00 pm

Study Groups1:00 pm – 2:00 pm

Abstract Sessions2:30 pm – 4:00 pm4:30 pm – 6:00 pm

#ACR17 Tweet Up4:30 pm – 6:00 pm

Industry-Supported Symposia6:30 pm – 9:30 pm

D A Y - A T - A - G L A N C E

13

STARTTIME

ENDTIME


CMECREDITS


ROOM

Sunday, Nov. 5 Scientific Sessions


7:30 AM

8:30 AM

3S001 ACR: Toll-like Receptors, Transporters & Interferons: Pathogenesis of Autoimmune DiseaseMODERATOR: Mary K. Crow

SPEAKERS: Argyrios N. Theofilopoulos

1 Basic Science 33 C

7:30 AM

8:30 AM

3S002 ACR: Year in ReviewMODERATOR: Richard F. Loeser

SPEAKERS: Richard M. Pope, Daniel H. Solomon

1 Clinical Science Hall B1

7:30 AM

8:30 AM

3S003 Networking: ACR/ARHP Annual Meeting First-Timers Orientation

0 11 B

7:45 AM

9:15 AM

3S004 MTP: 001 – Controversies in Sjögren's Syndrome $SPEAKER: Frederick B Vivino

1.5 Clinical Practice Fellows-in-Training

Hilton – Indigo BR A

7:45 AM

9:15 AM

3S005 MTP: 002 – Dermatological Manifestations of Rheumatic Diseases $SPEAKER: Laura Winterfield

1.5 Clinical Practice Hilton – Indigo BR B

7:45 AM

9:15 AM

3S006 MTP: 003 – Pain: Evaluation & Treatment of Back Pain $SPEAKER: David G. Borenstein

1.5 Clinical Practice Pain Management, Patient Safety

Hilton – Indigo BR C

7:45 AM

9:15 AM

3S007 MTP: 004 – Polymyalgia Rheumatica $SPEAKER: Robert F. Spiera

1.5 Clinical Practice Fellows-in-Training,

Patient Safety

Hilton – Indigo BR D

7:45 AM

9:15 AM

3S008 MTP: 005 – Pulmonary Manifestations of Rheumatic Disease $SPEAKER: Paul F. Dellaripa


Hilton – Indigo BR E

7:45 AM

9:15 AM

3S009 MTP: 006 – Rheum Care in Clinical Practice: Moving from Measurement to Management $SPEAKER: Eric Newman


Patient Safety

Hilton – Indigo BR H

7:45 AM

9:15 AM

3S010 MTP: 007 – RA: Biological Agents $SPEAKER: Joan M. Bathon


Patient Safety

Hilton – Indigo 202 A

7:45 AM

9:15 AM

3S011 MTP: 008 – Ultrasound versus Dual CT in Gout $SPEAKER: Ralf G. Thiele

1.5 Clinical Practice Hilton – Indigo 202 B

7:45 AM

9:15 AM

3S012 MTP: 009 – Vasculitis Mimics $SPEAKER: Tanaz A. Kermani





STARTTIME

ENDTIME


CMECREDITS


ROOM

7:45 AM

9:45 AM

3S013 Workshop: 201 – Advanced MSUS: Image Optimization & Pathology Recognition $SPEAKER: Jay B. Higgs, Catherine Bakewell

2 Clinical Practice Hilton Aqua Salon D

8:30 AM

10:00 AM

3S014 ACR: From Genes to Therapy in Autoimmune DiseasesMODERATORS: Marta Alarcón-Riquelme, Pravitt R. Gourh

SPEAKER: Soumya Raychaudhuri, Edward K. Wakeland

1.5 Basic Science Fellows-in-Training, Pediatrics

29 D

8:30 AM

10:00 AM

3S015 ACR: ANCA-Associated Vasculitis: News from the Cutting EdgeMODERATORS: Philip Seo, Eli Miloslavsky

SPEAKER: Christian Pagnoux, Michael E. Wechsler


8:30 AM

10:00 AM

3S016 ACR: Holy MACRA! How to Survive & Thrive in the New Era of MACRA, MIPS & APMsMODERATORS: Angus Worthing, Elizabeth Blair Solow

SPEAKERS: Angus Worthing, Ed Herzig, Kwas Huston


Practice Manager

6 D

8:30 AM

10:00 AM

3S017 ACR: Scleroderma: Assessment & Management of Vascular ManifestationsMODERATORS: Monique Hinchcliff, Anna-Maria Hoffmann-Vold

SPEAKERS: Ruth Minkin, John Pauling, Christopher Denton

1.5 Clinical Science 30 E

8:30 AM

10:00 AM

3S018 ACR: What Can We Learn From Monogenic Interferonopathies?MODERATOR: Hanna Kim

SPEAKERS: Yanick J Crow, Raphaela Goldbach-Mansky

1.5 Clinical Science 31 C

9:00 AM

10:00 AM

3S019 ACR: Missing Microbes: Lost From Our ClinicsMODERATOR: Gregg J. Silverman

SPEAKER: Martin Blaser

1 Basic Science 6 A

9:00 AM

10:00 AM

3S020 ARHP: Keynote Address: Exercise Is Medicine: We All Need to Say the Same ThingMODERATOR: Christine A. Stamatos

SPEAKERS: Teresa J. Brady, Alex Mroszczyk-McDonald

1 Clinical Practice Patient Safety 6 C

9:00 AM

11:00 AM

3S021 Posters: ACR/ARHP Poster Session A and Poster Tours

See page 70 or the Annual Meeting App for the full listing of Poster Tours.Poster Hall Morning Snack Break (8:30 AM – 9:30 AM)

2 Clinical Science Poster Hall C

15

STARTTIME

ENDTIME


CMECREDITS


ROOM



10:00 AM

5:00 PM

3S022 Exhibits

Exhibit Hall Morning Snack Break (10:00 AM)

Exhibit Hall Afternoon Snack Break (2:00 PM)

0 Exhibit Hall F-G

10:30 AM

11:15 AM

3S023 Exhibits: Innovation Theater A 0 Exhibit Hall F-G

10:30 AM

12:30 PM

3S024 Workshop: 202 – Clinical Anatomy & Physical Exam: Upper Extremity Regional Pain Syndromes $SPEAKERS: Robert A. Kalish, Pablo Villaseñor Ovies

2 Clinical Practice Pain Management, Patient Safety

Hilton – Aqua Salon E

10:30 AM

12:30 PM

3S025 Workshop: 203 – X-ray Challenges in Rheumatic Diseases $SPEAKER: Donald J. Flemming

2 Clinical Practice Hilton – Aqua Salon A

11:00 AM

12:00 PM

3S026 ACR: Anatomy for the Clinician I: Anatomy of the Ankle & Midfoot: The Source of Ankle PainMODERATORS: Gurjit S. Kaeley, Jasvinder A. Singh

SPEAKER: Ingrid Moller


28 A-E

11:00 AM

12:00 PM

3S027 ACR: Juvenile Dermatomyositis: Updates in Clinical Management & Biomarker DevelopmentMODERATORS: Susan Kim, Kaveh Ardalan

SPEAKERS: Claire Deakin, Adam Huber

1 Clinical Science Pediatrics 32 B

11:00 AM

12:00 PM

3S028 ACR: Leukocyte Migration & CommunicationMODERATOR: Theresa T. Lu

SPEAKER: Klaus Ley


11:00 AM

12:00 PM

3S029 ACR/ARHP: Reshaping the Relationship Between Physicians & PBMsMODERATOR: Colin Edgerton

SPEAKER: Sean Fahey

1 Business/Administration

Practice Manager

11 A

11:00 AM

12:00 PM

3S030 ARHP: Immunology Boot Camp I: Basis of Targeted TherapyMODERATOR: Sandro Perazzio

SPEAKER: Troy R. Torgerson

1 Clinical Practice 5 B

11:00 AM

12:00 PM

3S031 ARHP: FDA Audit: Are You Ready?MODERATOR: Donah Z. Crawford

SPEAKER: Lisa Kastanek

1 Clinical Science Ethics, Patient Safety, Practice

Manager

11 B

STARTTIME

ENDTIME


CMECREDITS


ROOM



11:00 AM

12:00 PM

3S032 ARHP: The Bare Bones of CartilageMODERATOR: Leonard H. Sigal

SPEAKERS: Ru Liu-Bryan, Tariq M Haqqi

1 Clinical Science Fellows-in-Training

10

11:00 AM

12:30 PM

3S033 ACR Abstract: Plenary Session I (826-830)SPEAKERS: Clara Dees, Jin Kyun Park, Jeffrey R. Curtis, Titilola Falasinnu, Jinoos Yazdany

1.5 Hall B1

11:30 AM

12:15 PM

3S034 Exhibits: Innovation Theater B 0 Exhibit Hall F-G

12:30 PM

1:15 PM


12:30 PM

2:00 PM

3S036 ACR: 2017 CARE: MOC Sessions 1 of 3: MyositisMODERATOR: Juliet Aizer

SPEAKER: Lisa Christopher-Stine

1.5 Clinical Practice 28 A-E

12:30 PM

2:00 PM

3S037 Networking: ARHP Discipline Round Tables: Networking Forum

0 Hilton – Sapphire BR A-B

12:45 PM

2:15 PM

3S038 ACR: Knowledge Bowl Preliminary RoundMODERATORS: Jonathan S. Hausmann, Sarah Doaty

SPEAKERS: Thomas Olenginski, Philip Dunn, Abraham Tacang, Rodolfo V Curiel, Marc Phillpotts, Erica McBride, William Traverse, Shriyanka Jain, John Zawidniak, Nasim A. Khan, Bhakti Joshi, Leeza Patel, Caroline McCulley, Anand Kumthekar, Julianna Desmarais, Robert J. Obrian, Patrick J. Mastin, Hector Medina, Florentina Berianu, Juan J Maya, Omar Tolyamat, Raquel Cuchacovich, Sarita Konka, Rose Chumo, Eli Miloslavsky, April Jorge, Mazen Nasrallah, Daniella Schwartz, Ananta Subedi, Sara Alehashemi, Ruben Peredo-Wende, Vivek Mehta, Tina Puthlaon-Kunnath, Stavros Savvas, Purva Chhibar, Huynh Tran, Angelica Vargas Guerrero, Nicole Mouneu Ornelas, Victor Alejandro Escamilla Gomez, Vladimir Liarski, Iazsmin Bauer Ventura, Pankti Reid, Robert L. DiGiovanni, Priyanka Murali, Eugene Jalbert, Parastoo Fazeli, Kimberly Rehberg, David Ewart


Training

20 A

12:45 PM

2:15 PM

3S039 MTP: 010 – Challenging Cases in Osteoporosis Management $SPEAKER: Nancy E. Lane



12:45 PM

2:15 PM

3S040 MTP: 011 – Crystal: Diagnosis & Management of Gout $SPEAKER: Susan Lee

1.5 Clinical Practice Pain Management

Hilton – Indigo BR B

12:45 PM

2:15 PM

3S041 MTP: 012 – Difficult Osteoporosis, DXA Dilemmas, & Novel Treatments $SPEAKER: Kenneth Saag



12:45 PM

2:15 PM

3S042 MTP: 013 – OA: Update 2017 $SPEAKER: Timothy E. McAlindon

1.5 Clinical Science Fellows-in-Training, Pain Management


17

STARTTIME

ENDTIME


CMECREDITS


ROOM



12:45 PM

2:15 PM

3S043 MTP: 014 – Pediatrics: Periodic Fevers in Children $SPEAKER: Seza Ozen

1.5 Clinical Practice Fellows-in-Training, Pediatrics


12:45 PM

2:15 PM

3S044 MTP: 015 – Pregnancy & Rheumatic Diseases $SPEAKER: Jill P. Buyon

1.5 Clinical Practice Patient Safety Hilton – Indigo BR H

12:45 PM

2:15 PM

3S045 MTP: 016 – Psoriatic Arthritis $SPEAKER: Christopher T. Ritchlin


Patient Safety


12:45 PM

2:15 PM

3S046 MTP: 017 – RA: Challenging Cases $SPEAKER: Veena K. Ranganath


12:45 PM

2:15 PM

3S047 MTP: 018 – SLE: Novel Treatments – How to Treat SLE $SPEAKER: Richard Furie

1.5 Clinical Practice Hilton – Indigo 204 A

12:45 PM

2:15 PM

3S048 MTP: 019 – Vaccinations for Patients on Biologic Therapies $SPEAKER: Jeffrey R. Curtis

1.5 Clinical Practice Ethics, Fellows-in-Training,

Patient Safety

Hilton – Indigo 204 B

1:00 PM

2:00 PM

3S049 ACR: CyTOF: Mass Cytometry to Probe Human Immune DiseaseMODERATOR: Alessandra B. Pernis

SPEAKER: Sean Bendall


1:00 PM

2:00 PM

3S050 ACR: Legislative & Regulatory Update 2017MODERATORS: Elizabeth Blair Solow, Angus Worthing

SPEAKER: Angus Worthing


Practice Manager

5 B

1:00 PM

2:00 PM

3S051 ACR: Medical Education Year in ReviewMODERATORS: Seth Berney, Beth L. Jonas

SPEAKER: Sterling West

1 Clinical Practice Educator, Fellows-in-

Training

23 A

1:00 PM

2:00 PM

3S052 ACR: Paging Dr. Lupus: Managing Clinical Emergencies in Patients With SLEMODERATORS: Daniel J. Wallace, Swamy Venuturupalli

SPEAKER: Rosalind Ramsey-Goldman

1 Clinical Practice 20 D

1:00 PM

2:00 PM

3S053 ACR: Pediatric Rheumatology Year in Review & AwardsMODERATOR: Natasha M. Ruth

SPEAKERS: Timothy Beukelman, Robert Colbert, Lucy Wedderburn, Natasha M. Ruth

1 Clinical Science Pediatrics 25 A

STARTTIME

ENDTIME


CMECREDITS


ROOM



1:00 PM

2:00 PM

3S054 ACR: Reactive Arthritis: 2017 UpdateMODERATORS: Jammie Barnes, Petros Efthimiou

SPEAKER: Robert D Inman

1 Clinical Science 6 A

1:00 PM

2:00 PM

3S055 ACR: Evelyn V. Hess, MD Memorial Lecture: SLE: Antibody-Secreting Cells and B CellsMODERATOR: Graciela S. Alarcón

SPEAKER: Ignacio Sanz

1 Basic Science 6 C

1:00 PM

2:00 PM

3S056 ACR: Using Social Media to Connect With & Recruit Patients for Research StudiesMODERATOR: Paul Sufka

SPEAKER: Katja Reuter

1 Clinical Practice Ethics, Patient Safety, Tech

Med

32 B

1:00 PM

2:00 PM

3S057 Study Group: Autoantibodies in Diagnosis & Follow up of Rheumatic DiseasesSPEAKERS: Tsuneyo Mimori, Marvin J. Fritzler, Mark H. Wener, Edward K.L. Chan, Minoru Satoh


1:00 PM

2:00 PM

3S058 Study Group: Capillaroscopy: The Safest Diagnostic Tool in RheumatologySPEAKERS: Maurizio Cutolo, Vanessa Smith, Alberto Sulli, Ariane L. Herrick

0 Clinical Practice 30 E

1:00 PM

2:00 PM

3S059 Study Group: From Clinics to Registries: Challenges in Ethnic Subsets with Rheumatic DiseaseSPEAKERS: Vaneet K. Sandhu, Sharon Dowell, Sheetal Desai

0 Clinical Science 29 D

1:00 PM

2:00 PM

3S060 Study Group: Macrophage Activation Syndrome (MAS)SPEAKERS: Randy Q. Cron, Edward M. Behrens


1:00 PM

2:00 PM

3S061 Study Group: Research Data Registries & RepositoriesSPEAKERS: Marina N. Magrey, Maria Antonelli


10

1:00 PM

2:00 PM

3S062 Study Group: Sjögren's Syndrome – From Improved Patient Stratification, Towards TreatmentSPEAKERS: Athanasios G. Tzioufas, Kathy Sivils, Jacques-Olivier Pers, Francesca Barone, Alan N. Baer

0 Clinical Practice 9

1:00 PM

2:00 PM

3S063 Study Group: Veterans AffairsSPEAKERS: Elizabeth Chang, Amy Joseph, Grant Cannon, Brian Sauer, J. Steuart Richards

0 Clinical Practice 11 A

19

STARTTIME

ENDTIME


CMECREDITS


ROOM



1:15 PM

3:15 PM

3S064 Workshop: 204 – Clinical Anatomy & Physical Exam: Lower Extremity Regional Pain Syndromes $SPEAKERS: Pablo Villaseñor Ovies, Robert A. Kalish



1:15 PM

3:15 PM

3S065 Workshop: 205 – MSUS: Basic $SPEAKERS: Gurjit S. Kaeley, Johannes Roth

2 Hilton – Aqua Salon D

1:15 PM

3:15 PM

3S066 Workshop: 206 – Synovial Fluid Analysis & Crystal Identification $SPEAKERS: Brian F. Mandell, Lan Chen

2 Clinical Practice Hilton – Aqua Salon C

1:30 PM

2:15 PM


2:30 PM

3:15 PM


2:30 PM

3:30 PM

3S069 ARHP: Transition: A Pediatric Lupus Patient Moves to the Adult ClinicMODERATOR: Talitha Cox

SPEAKERS: Kiana Johnson, Daisy Nguyen

1 Clinical Practice Patient Safety, Pediatrics

11 B

2:30 PM

4:00 PM

3S070 ACR Abstract: B Cell Biology & Targets in Autoimmune Disease (831-836)MODERATORS: Laurence Morel, John D. Mountz

SPEAKERS: Dario Ferri, Jennie Hamilton, Scott Jenks, Daniel L. Mueller, Yuriy Baglaenko, Hans U. Scherer


2:30 PM

4:00 PM

3S071 ACR Abstract: Epidemiology & Public Health I: Lung, Bone, & Infection Outcomes (837-842)MODERATORS: James Galloway, Jasvinder A. Singh

SPEAKERS: Jeffrey A. Sparks, Lindsy J. Forbess, Shanshan Sheehy, Masayoshi Harigai, Gulsen Ozen


2:30 PM

4:00 PM

3S072 ACR Abstract: Muscle Biology, Myositis & Myopathies (849-854)MODERATORS: Dana P. Ascherman, Siamak Moghadam-Kia

SPEAKERS: Iago Pinal-Fernandez, Xerxes Pundole, Silvia Martinez, Chiang-Ching Huang, Alexander Oldroyd, Takahisa Gono

1.5 Clinical Science 28 A-E

2:30 PM

4:00 PM

3S073 ACR Abstract: Pain–Basic & Clinical Aspects (855-860)MODERATOR: Terence Starz , David G. Borenstein

SPEAKERS: Peter C. Taylor, Yvonne C. Lee, Joshua Stefanik, Alyssa Wohlfahrt, Lisa Carlesso, Sarah Woller

1.5 Clinical Science Pain Management

31 C

STARTTIME

ENDTIME


CMECREDITS


ROOM



2:30 PM

4:00 PM

3S074 ACR Abstract: RA–Animal Models (861-866)MODERATORS: Miriam A. Shelef, Nunzio Bottini

SPEAKERS: Sho Sendo, Mattias N. D. Svensson, Adam Paul Croft, Andreas Ramming, Denise Beckmann, Patrice Decker

1.5 Basic Science 32 B

2:30 PM

4:00 PM

3S075 ACR Abstract: RA–Clinical Aspects I: Cardiac Comorbidities (867-872)MODERATORS: Veena K. Ranganath, Jon T. Giles

SPEAKERS: George Karpouzas, Sarah Skeoch, Pankhuri Gupta, Hitomi Kobayashi, Katherine P. Liao, Marjatta Leirisalo-Repo

1.5 Clinical Science 20 A

2:30 PM

4:00 PM

3S076 ACR Abstract: Sjögren's Syndrome I: Clinical Assessment & Trial Outcomes (873-878)MODERATOR: R. Hal Scofield

SPEAKERS: Jacques-Eric Gottenberg, Benjamin Fisher, Petra Budde, Soledad Retamozo, Valérie Devauchelle-Pensec, Alan N. Baer


2:30 PM

4:00 PM

3S077 ACR Abstract: SLE–Clinical & Treatment I: Novel & Current Therapies (885-890)MODERATORS Eliza Chakravarty, Lisa R. Sammaritano

SPEAKERS: David Wofsy, Victoria P Werth, Richard Furie, Joan T. Merrill,Tineke Kraaij


2:30 PM

4:00 PM

3S078 ACR Abstract: Spondyloarthropathies & Psoriatic Arthritis–Clinical & Treatment I (879-884)MODERATORS: Nigil Haroon, Denis Poddubnyy

SPEAKERS: Dilli Poudel, Désirée van der Heijde, Elizabeth G. Araujo, Keith Colaco, Jonathan Chan, Dafna D Gladman


2:30 PM

4:00 PM

3S079 ACR Abstract: Vasculitis I: Clinical Trials & Outcomes (891-896)MODERATORS: Rula A Hajj-Ali, Alfred Mahr

SPEAKERS: Yoshikazu Nakaoka, Vibeke Strand, Peter A. Merkel, Patrice Cacoub, Zachary S. Wallace, Amy Archer


2:30 PM

4:00 PM

3S080 ACR: Checkpoint Inhibitors & Immune-Related Adverse EventsMODERATOR: Laura Cappelli

SPEAKERS: Clifton O. Bingham III, Adam Mor


2:30 PM

4:00 PM

3S081 ACR: GREAT DEBATE: Biosimilars…To Switch or Not to Switch? That Is the QuestionMODERATORS: Daniel E. Furst, Daniel H. Solomon

SPEAKERS: Jonathan Kay, Roy Fleischmann

1.5 Clinical Practice Patient Safety Hall B1

21

STARTTIME

ENDTIME


CMECREDITS


ROOM



2:30 PM

4:00 PM

3S082 ACR: Spicing up Science Education: How to Effectively Incorporate Science into Med EdMODERATORS: Eli Miloslavsky, Kevin Byram

SPEAKERS: Christopher T. Ritchlin, Bethany A. Marston, Michael Pillinger, Sheetal Desai

1.5 Clinical Science Educator 23 A

2:30 PM

4:00 PM

3S083 ARHP Abstract: Psychosocial Impact on Rheumatic Disease (843-848)MODERATORS: Charmayne M. Dunlop-Thomas , W. Benjamin Nowell

SPEAKERS: Andrew Seto, Charmayne M. Dunlop-Thomas, Emilia Sato, Christine Rini, Desiree R Azizoddin, Erika Mosor

1.5 Clinical Science 9

2:30 PM

4:00 PM

3S084 ARHP: Improve Office Dynamics: What's Your Communication Sign?MODERATOR: Stacey Busch

SPEAKERS: George Munoz, Marcie Reiss


Patient Safety, Practice

Manager

5 B

2:30 PM

4:00 PM

3S085 ARHP: Keep'em Moving: Mobility Disability in Research & Patient CareMODERATOR: Una E. Makris

SPEAKERS: Stephanie Studenski, Daniel White

1.5 Clinical Science Pain Management, Patient Safety

11 A

2:30 PM

4:00 PM

3S086 ARHP: The Patient/Provider Dance: Enhancing Shared Decision MakingMODERATOR: Donah Z. Crawford

SPEAKERS: Adena Batterman, Jillian Rose, Joan Westreich

1.5 Clinical Practice Patient Safety 10

3:30 PM

4:15 PM


4:00 PM

6:00 PM

3S088 Workshop: 207 – Optimizing the EHR for Maximizing Productivity in the Rheumatology Clinic $SPEAKERS: Salahuddin Kazi

2 Clinical Practice Fellows-in-Training,

Patient Safety

Hilton – Aqua Salon A

4:00 PM

6:00 PM

3S089 Workshop: 208 – Pediatric Musculoskeletal Ultrasound Workshop $SPEAKERS: Johannes Roth, Daniel Windschall

2 Clinical Practice Fellows-in-Training, Pediatrics

Hilton – Aqua Salon D

4:00 PM

6:00 PM

3S090 Workshop: 209 – Physical Examination: Synovitis & Cervical Thoracolumbar Disorders $SPEAKERS: Edward C. Keystone



4:00 PM

6:00 PM

3S091 Workshop: 210 – When is Muscle Biopsy Helpful in the Evaluation & Management of Myopathy $SPEAKERS: Andrew Mammen

2 Clinical Practice Fellows-in-Training

Hilton – Aqua Salon C

STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

3S092 ACR Abstract: Biology & Pathology of Bone & Joint (902-906)MODERATORS: Matlock A. Jeffries, Mary Nakamura

SPEAKERS: Benjamin Rauwel, Martijn H. van den Bosch, Paloma Lopez de Figueroa, Carmen Corciulo, Silvia Monteagudo

1.5 Basic Science 29 D

4:30 PM

6:00 PM

3S093 ACR Abstract: Edmond L. Dubois, MD Memorial Lecture: SLE–Basic Science (897-901)MODERATORS: Susan A. Boackle, Dwight H. Kono

SPEAKERS: J. Michelle Kahlenberg, Jeremy Tilstra, Philip Carlucci, Ariel Stock, Neelakshi R. Jog


4:30 PM

6:00 PM

3S094 ACR Abstract: Education (907-912)MODERATORS: Deana M. Lazaro, Bernadette C. Siaton

SPEAKERS: Andrea Barker, Erica Jaffe, Michael J. Battistone, Rebecca Sadun, Jason Weiner, Huynh Tran


4:30 PM

6:00 PM

3S095 ACR Abstract: Epidemiology & Public Health II: Non-Genetic RFs for Incident Disease (913-918)MODERATORS: Jeffrey A. Sparks, Emily C. Somers

SPEAKERS: Benjamin Fisher, Anna Ilar, Jessica Williams, Olov Ekwall, Charles Eaton, Robin M ten Brinck


4:30 PM

6:00 PM

3S096 ACR Abstract: Healthcare Disparities in Rheumatology (919-924)MODERATORS: Amanda Sammut, Jim C. Oates

SPEAKERS: Elaine F. Remmers, Candace H. Feldman, George Karpouzas, Britney Jones, Susan M. Goodman, Elizabeth Ferucci


4:30 PM

6:00 PM

3S097 ACR Abstract: OA–Clinical Aspects I: Structural Progression & Incidence (931-936)MODERATORS: Stephen P. Messier, Grace H. Lo

SPEAKERS: Raveendhara R. Bannuru, Alexandra Wink, Zhaoli (Joy) Dai, Herbert S. B. Baraf, Yusuf Yazici, Alison H. Chang


4:30 PM

6:00 PM

3S098 ACR Abstract: Pediatric Rheum–Pathogenesis & Genetics (937-942)MODERATORS: Theresa T. Lu, Edward M. Behrens

SPEAKERS: Evan Tarbell, Eric Weiss, Adriana Almeida de Jesus, Michael J. Ombrello, Margarita Ivanchenko, Jae Jin Chae

1.5 Basic Science Pediatrics 32 B

4:30 PM

6:00 PM

3S099 ACR Abstract: Systemic Sclerosis, Fibrosing Syns & Raynaud's–Clinical & THR I (943-948)MODERATORS: Mandana Nikpour, Fabian A Mendoza

SPEAKERS: Elizabeth R. Volkmann, Devon Charlton, Jennifer G Walker, Nadia D. Morgan, Anna-Maria Hoffmann-Vold, Vandana Bhushan


23

STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

3S100 ACR Abstract: T Cell Biology & Targets in Autoimmune Disease (949-954)MODERATORS: Daniel L. Mueller, Laura T. Donlin

SPEAKERS: Annalisa Pianta, Eleni Tiniakou, Cliff Rims, Takayuki Katsuyama, Salvatore Albani, Nan Shen

1.5 Basic Science 33 C

4:30 PM

6:00 PM

3S101 ACR: Chondrocytes: To Live or Let Die?MODERATORS: Anne-Marie Malfait, Tom Appleton

SPEAKERS: Matthew Warman, Robert Mauck, Martin Lotz


4:30 PM

6:00 PM

3S102 ACR: Curbside Consults: Ask the ProfessorsMODERATORS: Mathilde H Pioro, Seth Berney

SPEAKERS: Ellen M. Ginzler, Julius Birnbaum, Victoria Werth

1.5 Clinical Practice 20 A

4:30 PM

6:00 PM

3S103 ACR: Natural History & Treatment of Inflammatory Back PainMODERATOR: Grant H. Louie

SPEAKERS: John D. Reveille, Christopher T. Ritchlin


Hall B1

4:30 PM

6:00 PM

3S104 ACR: Update in RA: Benefits & Harms of Biologics & Small Molecules & Imaging StrategiesMODERATORS: Rodney Tehrani, Elizabeth Blair Solow

SPEAKERS: Mark C. Genovese, Peter C. Taylor, Kevin Winthrop


20 D

4:30 PM

6:00 PM

3S105 ACR/ARHP: Patient Engagement in Research: Best Practices, Benefits & ChallengesMODERATORS: Elizabeth A. Schlenk, Tanja Stamm

SPEAKERS: Maarten de Wit, Suzanne Schrandt, Janet L. Poole


4:30 PM

6:00 PM

3S106 ARHP Abstract: Clinical Practice/Patient Care/Health Services Research (925-930)MODERATORS: Stacey Busch, Alyssa B. Dufour

SPEAKERS: Jeffrey R. Curtis, Yvonne M. Golightly, Kim Jones, Fei Xiao, Elisabet Welin Henriksson, Marianna Meroni


4:30 PM

6:00 PM

3S107 ARHP: Update: Vitamin D & Rheumatic DiseasesMODERATOR: Leonard H. Sigal

SPEAKERS: Gina Woods, Yehuda Shoenfeld

1.5 Clinical Science Fellows-in-Training

11 A

4:30 PM

6:00 PM

3S108 ARHP: Access to Non-Pharmacological Using a Stepped Care Approach: International PerspectivesMODERATOR: Marie Westby

SPEAKERS: C.H.M. van den Ende, Sara Falkner

1.5 Clinical Practice Practice Manager

9

STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

3S109 ARHP: Your New Role in the Era of MACRA: Tips & Tools for Rheumatology StaffMODERATOR: Barbara Slusher

SPEAKERS: Terence Starz, Theodore Pincus, Janet Bahr


Practice Manager

11 B

4:30 PM

6:00 PM

3S110 MTP: 020 – Adult Inflammatory Myopathy $SPEAKERS: Frederick W Miller



4:30 PM

6:00 PM

3S111 MTP: 021 – Antiphospholipid Syndrome $SPEAKERS: Doruk Erkan

1.5 Clinical Practice Patient Safety Hilton – Indigo BR B

4:30 PM

6:00 PM

3S112 MTP: 022 – Cutaneous Vasculitis $SPEAKERS: Rebecca L. Manno

1.5 Clinical Practice Hilton – Indigo BR C

4:30 PM

6:00 PM

3S113 MTP: 023 – Infections with Biologics $SPEAKERS: Arthur Kavanaugh


Patient Safety


4:30 PM

6:00 PM

3S114 MTP: 024 – Inflammatory Eye Disease/Uveitis $SPEAKERS: Debra Anne Goldstein



4:30 PM

6:00 PM

3S115 MTP: 025 – Management of Difficult Raynaud's & Digital Ischemia $SPEAKERS: Thomas A. Medsger Jr.


Patient Safety


4:30 PM

6:00 PM

3S116 MTP: 026 – Pediatric Rheumatology for Adult Rheumatologists $SPEAKERS: Patience H. White



4:30 PM

6:00 PM

3S117 MTP: 027 – Safety of Drugs Used to Treat RA $SPEAKERS: Eric M. Ruderman

1.5 Clinical Practice Patient Safety Hilton – Indigo 202 B

4:30 PM

6:00 PM

3S118 MTP: 028 – SLE: Lupus Nephritis $SPEAKERS: Rosalind Ramsey-Goldman


4:30 PM

6:00 PM

3S119 MTP: 029 – Systemic Sclerosis: Disease Staging & Subsetting in Clinical Practice $SPEAKERS: Daniel E. Furst



4:30 PM

6:00 PM

3S120 Networking: #ACR17 Tweet Up 0 5 B

6:30 PM

9:30 PM

3S121 Exhibits: Industry-Supported Symposia 0 See page 66 or the Annual

Meeting App for the full listing of

symposia.

MONDAYN O V E M B E R 6 , 2 0 1 7




Poster Session B and Poster Tours9:00 am – 11:00 am



Innovation Theater A10:30 am – 11:15 am12:30 pm – 1:15 pm2:30 pm – 3:15 pm

Innovation Theater B11:30 am – 12:15 pm1:30 pm – 2:15 pm3:30 pm – 4:15 pm

ACR Plenary Session II11:00 am - 12:30 pm

ARHP Discipline Round Tables: Networking Forum (Hilton Bayfront)12:30 pm – 2:00 pm



ACR Career Fair (Hilton Bayfront)6:00 pm – 8:00 pm


27

STARTTIME

ENDTIME


CMECREDITS


ROOM

Monday, Nov. 6 Scientific Sessions


7:30 AM

8:30 AM

4M001 ACR: FDA Update on Safety Issues in the Treatment of Rheumatic DiseaseMODERATORS: Arthur Kavanaugh, Michael Weisman

SPEAKERS: Nikolay Nikolov, Rachel Glaser, Juwaria Waheed

1 Clinical Science Patient Safety 31 C

7:30 AM

8:30 AM

4M002 ACR: Getting to the Heart of the Matter: The Heart in Autoimmune DiseasesMODERATORS: Petros Efthimiou, Adey Berhanu

SPEAKER: Rekha Mankad

1 Clinical Science Educator, Fellows-in-

Training, Practice

Manager

20 D

7:30 AM

8:30 AM

4M003 ACR: Paul Klemperer, MD Memorial Lecture: TNF Inhibitors: Conquering RA by Molecular TargetingMODERATOR: Abby Abelson

SPEAKER: Ravinder N. Maini


7:30 AM

8:30 AM

4M004 ACR: The Great (Educational) Debate: Milestones: Meaningful vs. MillstoneMODERATOR: Lisa Criscione-Schreiber

SPEAKERS: Calvin Brown Jr, Simon M. Helfgott


Training

25 A

7:30 AM

8:30 AM

4M005 ARHP: Fitness Interventions for Fatigue & Pain: Navigate Your Patient's ChallengesMODERATOR: Catherine A. McAuley

SPEAKERS: Daniel J. Clauw, David Williams


11 A

7:30 AM

8:30 AM

4M006 ARHP: From Bench to Bedside: Using Implementation Science to Improve RheumatologyMODERATOR: Kelli Allen

SPEAKER: Daniel H. Solomon

1 Clinical Science 11 B

7:30 AM

8:30 AM

4M007 ARHP: Immunology Boot Camp II: Basic Mechanisms of AutoimmunityMODERATORS: Sandro Perazzio, Susan Chrostowski

SPEAKER:Troy R. Torgerson


7:45 AM

9:15 AM

4M008 MTP: 030 – Antiphospholipid Syndrome $SPEAKERS: Munther A Khamashta, David P. D’Cruz

1.5 Clinical Practice Hilton – Indigo BR A

7:45 AM

9:15 AM

4M009 MTP: 031 – Approaches to Urticaria & Angiodema $SPEAKER: Bruce L. Zuraw


7:45 AM

9:15 AM

4M010 MTP: 032 – Controversies in Sjögren's Syndrome $SPEAKER: Frederick B Vivino

1.5 Clinical Practice Hilton – Indigo BR C

STARTTIME

ENDTIME


CMECREDITS


ROOM



7:45 AM

9:15 AM

4M011 MTP: 033 – Dermatological Manifestations of Rheumatic Diseases $SPEAKER: Laura Winterfield

1.5 Clinical Practice Hilton – Indigo BR D

7:45 AM

9:15 AM

4M012 MTP: 034 – Macrophage Activation Syndrome $SPEAKER: Rayfel Schneider

1.5 Clinical Practice Pediatrics Hilton – Indigo BR E

7:45 AM

9:15 AM

4M013 MTP: 035 – Myopathy: Issues in Diagnosis & Treatment $SPEAKER: Mary E. Cronin



7:45 AM

9:15 AM

4M014 MTP: 036 – Reactive Arthritis: An Update $SPEAKER: Siba P. Raychaudhuri

1.5 Clinical Practice Fellows-in-Training, Pain Management


7:45 AM

9:15 AM

4M015 MTP: 037 – RA: Biological Agents CANCELLED $SPEAKER: Joan M. Bathon


Patient Safety


7:45 AM

9:15 AM

4M016 MTP: 038 – Vasculitis: Update $SPEAKER: Carol A. Langford



7:45 AM

9:15 AM

4M017 MTP: 081 – Hypermobility $SPEAKER: Eric Gall



7:45 AM

9:45 AM

4M018 Workshop: 211 – Advanced MSUS: Image Optimization & Pathology Recognition $SPEAKERS: Jay B. Higgs, Catherine Bakewell



7:45 AM

9:45 AM

4M019 Workshop: 212 – How to Use Motivational Interviewing Skills in the Routine Rheum Practice $SPEAKERS: Steven Cole, R. Ellen Pearlman


7:45 AM

9:45 AM

4M020 Workshop: 213 – Nailfold Capillarscopy Made Easy for the Clinician $SPEAKERS: Maurizio Cutolo, Vanessa Smith


8:30 AM

10:00 AM

4M021 ACR: Evolution of MHC: Impact on ImmunopathogenesisMODERATOR: Robert D Inman

SPEAKERS: Peter Parham, Allen Steere, James T. Rosenbaum


8:30 AM

10:00 AM

4M022 ACR: Giant Cell Arteritis—2017 UpdateMODERATOR: Rebecca L. Manno

SPEAKERS: Cornelia M. Weyand, Tanaz A. Kermani, Peter C. Grayson


29

STARTTIME

ENDTIME


CMECREDITS


ROOM



8:30 AM

10:00 AM

4M023 ACR: Pediatric Vasculitis: Insights From ARCHiVE & ADA2 DeficiencyMODERATORS: Marinka Twilt, Troy R. Torgerson

SPEAKERS: David Cabral, Paul Brogan, Ivona Aksentijevich

1.5 Clinical Science Pediatrics 24 A

8:30 AM

10:30 AM

4M024 ACR: Early Arthritis – “Making Connections Count!” Presented by EULARSPEAKERS: Iain B. McInnes, Gerd R. Burmester, J.W.J. Bijlsma, Tanja Stamm


9:00 AM

10:00 AM

4M025 ACR: Biosimilar Medicine: Changing Landscape in Health CareMODERATOR: Colin Edgerton

SPEAKERS: Jonathan Kay, Angus Worthing

1 Clinical Practice 31 C

9:00 AM

10:00 AM

4M026 ACR: CPC: Fever & Cytopenia in a Lupus Patient: Nothing Is as Simple as It SeemsMODERATORS: Irene J. Tan, Petros Efthimiou

SPEAKER: Chelsey Forbess Smith


Training

6 A

9:00 AM

10:00 AM

4M027 ACR: How to Disseminate Your Research & Manage Your Online ReputationMODERATOR: Jonathan S. Hausmann

SPEAKER: Katja Reuter

1 Clinical Practice Ethics, Patient Safety, Tech

Med

32 B

9:00 AM

10:00 AM

4M028 ACR: Immunology Update: IL-6 Signaling from Bench to BedsideMODERATOR: Leonard H. Calabrese

SPEAKER: Stefan Rose-John


9:00 AM

10:00 AM

4M029 ACR: Treatment for RA in Patients with Concomitant Cardiovascular DiseaseMODERATORS: Elizabeth Chang, Jasvinder A. Singh

SPEAKERS: Joan M. Bathon, Katherine P. Liao

1 Clinical Science Patient Safety 20 D

9:00 AM

10:00 AM

4M030 ARHP: Distinguished Lecturer: Moving Toward Better Osteoarthritis Management MODERATOR: Christine A. Stamatos

SPEAKER: Kelli Allen


9:00 AM

11:00 AM

4M031 Posters: ACR/ARHP Poster Session B and Poster Tours



STARTTIME

ENDTIME


CMECREDITS


ROOM



10:00 AM

5:00 PM

4M032 ExhibitsExhibit Hall Morning Snack Break (10:00 AM) Exhibit Hall Afternoon Snack Break (2:00 PM)

0 Exhibit Hall F-G

10:30 AM

11:15 AM

4M033 Exhibits: Innovation Theater A 0 Exhibit Hall F-G

9:30 AM

10:30 AM

4M034 ACR: Rheumatology in Africa: Pattern, Practice and Prospects. Presented by AFLARSPEAKERS: Yerima Abubakar, Paul Ekwom, Omondi Oyoo, Olufemi Adelowo, Samy Slimani, Marie Doualla Bija


10:30 AM

12:30 PM

4M035 Workshop: 214 – Beyond MSUS for Rheumatologists $SPEAKERS: Minna J. Kohler, Andreas P Diamantopoulos, Paul DeMarco , Paul McCorkell



10:30 AM

12:30 PM

4M036 Workshop: 215 – Joint Injections (Knee, Ankle, Shoulder & Wrist) $SPEAKERS: Jemima Albayda, Pari Basharat

2 Clinical Practice Fellows-in-Training,

Patient Safety


10:30 AM

12:30 PM

4M037 Workshop: 216 – Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice $SPEAKERS: Philip G. Conaghan, Mikkel Østergaard



10:30 AM

12:30 PM

4M038 Workshop: 217 – Renal Histopathology in SLE & Vasculitis $SPEAKER: Anthony Chang


11:00 AM

12:00 PM

4M039 ACR: Anatomy for the Clinician II: Neuroanatomy Upper EXT: Nerve Entrapment to Nerve BlocksMODERATORS: Gurjit S. Kaeley, Jasvinder A. Singh

SPEAKER: Carlo Martinoli

1 Clinical Practice Educator, Pain Management,

Pediatrics

30 E

11:00 AM

12:00 PM

4M040 ACR: Juvenile Spondyloarthritis: Updates in Evaluation, Mgt, & PathophysiologyMODERATORS: Judith Smith, Shirley M.L. Tse

SPEAKERS: Pamela F. Weiss, Robert Colbert

1 Clinical Science Fellows-in-Training,

Pediatrics, Practice

Manager

23 A

31

STARTTIME

ENDTIME


CMECREDITS


ROOM



11:00 AM

12:00 PM

4M041 ACR: Knowledge Bowl Final RoundMODERATORS: Jonathan S. Hausmann, Sarah Doaty

SPEAKERS: Nasim A. Khan, Bhakti Joshi, Leeza Patel, Julianna Desmarais, Caroline McCulley, Anand Kumthekar, Robert J. Obrian, Patrick J. Mastin, Hector Medina, Florentina Berianu, Juan J Maya, Omar Tolyamat, Raquel Cuchacovich, Sarita Konka, Rose Chumo, Eli Miloslavsky, April Jorge, Mazen Nasrallah, Daniella Schwartz, Ananta Subedi, Sara Alehashemi, Ruben Peredo-Wende, Vivek Mehta, Tina Puthlao-Kunnath, Stavros Savvas, Purva Chhibar, Huynh Tran, Angelica Vargas Guerrero, Nicole Mouneu Ornelas, Victor Alejandro Escamilla Gomez, Vladimir Liarski, Iazsmin Bauer Ventura, Pankti Reid, Robert L. DiGiovanni, Priyanka Murali, Eugene Jalbert, Parastoo Fazeli, Kimberly Rehberg, David Ewart, Thomas Olenginski, Philip Dunn, Abraham Tacang, Rodolfo V Curiel, Marc Phillpotts, Erica McBride, William Traverse, Shriyanka Jain, John Zawidniak


Training

20 A

11:00 AM

12:00 PM

4M042 ACR: Therapeutic Genome Editing: Prospects & ChallengesMODERATORS: Cong-Qiu Chu

SPEAKERS: Christof Fellmann

1 Basic Science 32 B

11:00 AM

12:00 PM

4M043 ACR/ARHP: Research Opportunities for Using Existing Rheumatology DatasetsMODERATORS: Rebecca J. Cleveland, Alyssa B. Dufour

SPEAKERS: Kaleb Michaud, Nigel Arden


11:00 AM

12:00 PM

4M044 ARHP: Educational Opportunities for Arthritis HPs: North America and BeyondMODERATOR: Marie Westby

SPEAKERS: Benjamin J Smith, Sameer Chunara

1 Clinical Practice Educator 10

11:00 AM

12:00 PM

4M045 ARHP: Physical Activity & Psychosocial Aspects of ArthritisMODERATOR: Mary Margaretten

SPEAKER: Patricia P. Katz


11 A

11:00 AM

12:00 PM

4M046 ARHP: Update: Large-Vessel VasculitisMODERATOR: Jason Springer

SPEAKERS: Tanaz A. Kermani, Antoine G. Sreih


11:00 AM

12:30 PM

4M047 ACR Abstract: Plenary Session II (1784-1789)SPEAKERS: Benjamin Fisher, Christina D Chambers, Gregg J. Silverman, Robert B.M. Landewé, Guang-hua Lei, Zachary S. Wallace

1.5 Hall B1

STARTTIME

ENDTIME


CMECREDITS


ROOM



11:30 AM

12:15 PM

4M048 Exhibits: Innovation Theater B 0 Exhibit Hall F-G

12:00 PM

2:00 PM

4M049 Networking: ARHP Topic Round Tables: Networking Forum


Hilton – Sapphire BR A-B

12:30 PM

1:15 PM


12:30 PM

2:00 PM

4M051 ACR: 2017 CARE: MOC Sessions 2 of 3: Metabolic Bone DiseaseMODERATOR: Allan C. Gelber

SPEAKERS: Chad Deal


12:30 PM

2:00 PM

4M052 ACR: Not all Fibrosis is SclerodermaMODERATORS: Victoria K. Shanmugam, Shervin Assassi

SPEAKERS: John H. Stone, Alisa Femia, Laura K. Hummers


12:45 PM

2:15 PM

4M053 MTP: 039 – Axial Spondyloarthritis/Ankylosing Spondylitis $SPEAKERS: Liron Caplan


Patient Safety


12:45 PM

2:15 PM

4M054 MTP: 040 – Challenging Cases in Osteoporosis Management $SPEAKERS: Nancy E. Lane



12:45 PM

2:15 PM

4M055 MTP: 041 – Crystal: Diagnosis & Management of Gout $SPEAKERS: John Fitzgerald



12:45 PM

2:15 PM

4M056 MTP: 042 – Pregnancy & Rheumatic Diseases $SPEAKERS: Jill P. Buyon


Patient Safety


12:45 PM

2:15 PM

4M057 MTP: 043 – Psoriatic Arthritis $SPEAKERS: Christopher T. Ritchlin


Patient Safety


12:45 PM

2:15 PM

4M058 MTP: 044 – Pulmonary Manifestations of Rheumatic Disease $SPEAKERS: Paul F. Dellaripa

1.5 Clinical Practice Hilton – Indigo BR H

12:45 PM

2:15 PM

4M059 MTP: 045 – RA: Challenging Cases $SPEAKERS: James R. O’Dell



33

STARTTIME

ENDTIME


CMECREDITS


ROOM



12:45 PM

2:15 PM

4M060 MTP: 046 – Survival Strategies: Seeking, Joining, Thriving in Private Practice $SPEAKERS: Herbert S. B. Baraf

1.5 Clinical Practice Fellows-in-Training, Practice

Manager, Trainee


12:45 PM

2:15 PM

4M061 MTP: 047 – SLE: Lupus Nephritis $SPEAKERS: Rosalind Ramsey-Goldman



12:45 PM

2:15 PM

4M062 MTP: 048 – Vasculitis: Factors That Influence Disease Patterns $SPEAKERS: Kenneth J. Warrington


1:00 PM

2:00 PM

4M063 ACR: Precision Medicine for Rheumatic Disease: Closer Than You Think?MODERATOR: Diane L. Kamen

SPEAKERS: Maria Virginia Pascual

1 Basic Science 29 D

1:00 PM

2:00 PM

4M064 ACR: Tech Tools for Rheumatology, Version 3.0MODERATOR: Jonathan S. Hausmann

SPEAKERS: Suleman Bhana

1 Clinical Practice Tech Med 32 B

1:00 PM

2:00 PM

4M065 ACR: Update on Amyloidosis 2017MODERATORS: Arthur Weinstein, Peter Gorevic

SPEAKERS: Mark Pepys

1 Clinical Science 6 D

1:00 PM

2:00 PM

4M066 Study Group: Aging Research in RheumatologySPEAKERS: Devyani Misra, Una E. Makris, Rebecca L. Manno


1:00 PM

2:00 PM

4M067 Study Group: Calcinosis in Juvenile & Adult DermatomyositisSPEAKERS: Lorinda Chung, Jiri Vencovsky, Adam Schiffenbauer, Lesley Ann Saketkoo, Clarissa A. Pilkington


1:00 PM

2:00 PM

4M068 Study Group: Cancer Immunotherapy & Rheumatologic DiseaseSPEAKERS: Laura Cappelli, Noha Abdel-Wahab, Jan Leipe, Maria Suarez-Almazor, Leonard H. Calabrese


1:00 PM

2:00 PM

4M069 Study Group: Challenges for MSUS in Daily Practice in Latin AmericaSPEAKERS: Loreto Massardo, Marwin Gutierrez, Johannes Roth


1:00 PM

2:00 PM

4M070 Study Group: Childhood Sjogren SyndromeSPEAKERS: Jay Mehta, Scott Lieberman


STARTTIME

ENDTIME


CMECREDITS


ROOM



1:00 PM

2:00 PM

4M071 Study Group: Developing Support and Education Programs for People with Rheumatologic IllnessSPEAKERS: Adena Batterman


1:00 PM

2:00 PM

4M072 Study Group: Haemochromatosis Arthropathy Study GroupSPEAKERS: Patrick Kiely, Stephanie Finzel, Graeme Carroll


1:00 PM

2:00 PM

4M073 Study Group: Juvenile Arthritis Workgroup (JAW) – TMJ ArthritisSPEAKERS: Randy Q. Cron, Nikolay Tzaribachev


1:00 PM

2:00 PM

4M074 Study Group: PsA Bench to Bedside: Quantifying Disease Severity & Cutting Edge TherapiesSPEAKERS: Siba P. Raychaudhuri, Christopher T. Ritchlin, Alexis Ogdie, Joseph F. Merola, Jinoos Yazdany, Junko Takeshita

0 11 B

1:00 PM

2:00 PM

4M075 Study Group: Research Advances in RA in Asia-Pacific AreaSPEAKERS: Yeong Wook Song, Tsutomu Takeuchi


1:00 PM

2:00 PM

4M076 Study Group: SPARTAN-ASAS SpondyloarthritisSPEAKERS: Lianne S. Gensler, Robert B.M. Landewé


1:15 PM

3:15 PM

4M077 Workshop: 218 – How to Apply Statistics to Your Research $SPEAKERS: Dorothy D. Dunlop, Julia (Jungwha) Lee


1:15 PM

3:15 PM

4M078 Workshop: 219 – Integrating Complementary Therapies into your Practice $SPEAKERS: Randy Horwitz, Nisha J. Manek

2 Clinical Practice Fellows-in-Training, Pain Management, Patient Safety


1:15 PM

3:15 PM

4M079 Workshop: 220 – Joint Injection Techniques $SPEAKERS: Atul A. Deodhar, Kenneth S. O’Rourke



1:15 PM

3:15 PM

4M080 Workshop: 221 – Ultrasound in Large Vessel Vasculitis $SPEAKERS: Andreas P Diamantopoulos, Wolfgang A. Schmidt



1:30 PM

2:15 PM


2:30 PM

3:15 PM


35

STARTTIME

ENDTIME


CMECREDITS


ROOM



2:30 PM

3:30 PM

4M083 ARHP: Pharma Update: Safety, New Indications, Latest ApprovalsMODERATOR: Joni Dean

SPEAKER: Kamala Nola

1 Clinical Practice Patient Safety 9

2:30 PM

4:00 PM

4M084 ACR Abstract: Cytokines and Cell Trafficking: Unexpected Effects of Known Molecules (1790-1795)MODERATORS: Hendrik Schulze-Koops, Astrid Jungel

SPEAKERS: Nathalie Burg, Emmanuel Karouzakis, Erik Lubberts, Marije I. Koenders, Alexandre Virone


2:30 PM

4:00 PM

4M085 ACR Abstract: Measures & Measurement of Healthcare Quality (1796-1801)MODERATORS: Alison Bays, Leslie R Harrold

SPEAKERS: Daniel H. Solomon, Stephanie Giattino, Alfredo Aguirre, Nicole Bitencourt, Rebecca Trachtman, Winnie Nelson

1.5 Clinical Science 32 B

2:30 PM

4:00 PM

4M086 ACR Abstract: Patient Outcomes, Preferences, & Attitudes I (1802-1807)MODERATORS: Jennifer Barton, M. Elaine Husni

SPEAKERS: Francis Guillemin, George Karpouzas, Desiree R Azizoddin, Christine Willinger, Patricia P. Katz, Sam Norton


2:30 PM

4:00 PM

4M087 ACR Abstract: RA–Clinical Aspects II: Treatment Patterns (1814-1819)MODERATORS: Michelle J. Ormseth, Anthony Russell

SPEAKERS: Vivian P. Bykerk, Jeffrey R. Curtis, Michael Richter, Denis Choquette, SE Connolly, Caitrin Coffey


2:30 PM

4:00 PM

4M088 ACR Abstract: RA–SM Molecules, Biologics & Gene Ther I: Outcomes Therapy (1820-1825)MODERATORS: Allan Gibofsky, Stanley B Cohen

SPEAKERS: Veerle Stouten, Tsutomu Takeuchi, Mark C. Genovese, Samuel Bitoun, Kevin Winthrop, Michaela Koehm


2:30 PM

4:00 PM

4M089 ACR Abstract: Reproductive Issues in Rheumatic Disorders (1808-1813)MODERATOR: Nathalie Costedoat-Chalumeau, Bonnie L. Bermas

SPEAKERS: Chi Chiu Mok, Eliza Chakravarty, Maria Mouyis, Eliza Chakravarty, Julia F Simard, Kimberly Hays


2:30 PM

4:00 PM

4M090 ACR Abstract: SLE–Animal Models (1832-1837)MODERATORS: Chaim Putterman, Alessandra B. Pernis

SPEAKERS: Laurence Morel, Xiaoping Qing, Javier Rangel-Moreno, Carla Cuda, Elise Mike, William Stohl


STARTTIME

ENDTIME


CMECREDITS


ROOM



2:30 PM

4:00 PM

4M091 ACR Abstract: SLE–Clinical & Treatment II: Clinical Trial Design & Outcome Measure (1838-1843)MODERATORS: Andrea Doria, Maria Dall’Era

SPEAKERS: Mimi Kim, Michal Abrahamowicz, Sharzad Emamikia, Aikaterini Thanou, Michelle Petri, Vinicius Domingues


2:30 PM

4:00 PM

4M092 ACR Abstract: Spondyloarthropathies & Psoriatic Arthritis–Clinical & Treatment II (1826-1831)MODERATORS: Alexis Ogdie, Lihi Eder

SPEAKERS: Laura C Coates, David Sandoval Calderon, Karel Pavelka, Musaab Elmamoun, Ulrich Weber, Janneke de Winter


2:30 PM

4:00 PM

4M093 ACR Abstract: Vasculitis II: Biomarkers & Disease Activity (1844-1849)MODERATORS: Cornelia M. Weyand, Peter C. Grayson

SPEAKERS: Alvise Berti, Kaitlin A. Quinn, Anouk von Borstel, Niek de Vries, Ramnath Misra, Catherine E. Najem


2:30 PM

4:00 PM

4M094 ACR: Adiposity & ArthritisMODERATORS: Ru Liu-Bryan, Francis Berenbaum

SPEAKERS: Edgar Engleman, Timothy Griffin, Stephen Young


2:30 PM

4:00 PM

4M095 ACR: Controversies in Diagnosis & Mgt of Gout & Asymptomatic HyperuricemiaMODERATORS: Jasvinder A. Singh, N. Lawrence Edwards

SPEAKERS: Tuhina Neogi, Ralf G. Thiele, Michael Pillinger


Hall B1

2:30 PM

4:00 PM

4M096 ACR: Throw Me a Bone!: Update on Important Concepts in Bone-Related DiseasesMODERATORS: Fredrica Smith, E Michael Lewiecki

SPEAKERS: E Michael Lewiecki, Catherine Gordon, Stuart Goodman

1.5 Clinical Science Pediatrics 20 D

2:30 PM

4:00 PM

4M097 ACR/ARHP Abstract: Orthopedics & Rehabilitation Science (1850-1855)MODERATORS: Catherine A. McAuley, Beth L. Jonas

SPEAKERS: Guoqi Cai, Carlo Ammendolia, Rabih Nayfe, Aileen Ledingham, Jesse Christensen, Susan L. Murphy


2:30 PM

4:00 PM

4M098 ARHP: Psychosocial Considerations for Young Adults With Rheumatic DiseaseMODERATOR: Janet L. Poole

SPEAKERS: Liz Morasso, Jennifer Ziegler, Kristine Carandang

1.5 Clinical Practice Pediatrics 11 A

37

STARTTIME

ENDTIME


CMECREDITS


ROOM



2:30 PM

4:00 PM

4M099 ARHP: Stay on the Job: Assessments & Rehab Interventions for People With Inflammatory ArthritisMODERATOR: Kendra A. Young

SPEAKERS: Gareth T. Jones, Nancy A. Baker, Yeliz Prior


5 B

2:30 PM

4:00 PM

4M100 ARHP: Telehealth: Can It Expand the Rheumatology Workforce?MODERATORS: Deana Lazaro, John McDougall Jr.

SPEAKERS: Daniel Albert, Elizabeth Ferucci, Daniel F. Battafarano

1.5 Clinical Practice Patient Safety, Tech Med

11 B

3:30 PM

4:15 PM


4:00 PM

6:00 PM

4M102 Workshop: 222 – Dermatopathology of Rheumatic Diseases $SPEAKER: Daniel Miller


4:00 PM

6:00 PM

4M103 Workshop: 223 – Histopathology & Imaging of Rheumatic Lung Disease $SPEAKERS: Ganesh Raghu, Sudhakar Pipavath


4:00 PM

6:00 PM

4M104 Workshop: 224 – Joint Injections (Knee, Ankle, Shoulder & Wrist) $SPEAKERS: Jemima Albayda, Pari Basharat

2 Clinical Practice Hilton – Aqua Salon E

4:00 PM

6:00 PM

4M105 Workshop: 225 – Ultrasound Injection Guidance $SPEAKERS: Paul DeMarco, Gurjit S. Kaeley

2 Clinical Practice Hilton – Aqua Salon D

4:30 PM

6:00 PM

4M106 ACR Abstract: Fibromyalgia, Soft Tissue Disorders, & Regional and Specific Pain Syns (1868-1873)MODERATOR: Brian Walitt, Kim Jones

SPEAKERS: Ji-Hyoun Kang, Chad M. Brummett, Louis Lu, Jacob N. Ablin, Nilamba Jhala


4:30 PM

6:00 PM

4M107 ACR Abstract: Imaging of Rheumatic Diseases I: Novel Imaging & Scoring Systems (1874-1879)MODERATORS: Amanda Nelson, Minna J. Kohler

SPEAKERS: Stephanie Tom, S. van Beest, Thomas Osborn, Xenofon Baraliakos, Mads Ammitzbøll-Danielsen, Allen P. Anandarajah


4:30 PM

6:00 PM

4M108 ACR Abstract: Miscellaneous Rheumatic & Inflammatory Diseases I (1880-1885)MODERATORS: Mehrdad Maz, Petros Efthimiou

SPEAKERS: Michael Richter, Alexander Wu, Masataka Umeda, Yihan Cao, Jonathan Steinfeld, Bella Y. Mehta


STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

4M109 ACR Abstract: Osteoporosis & Metabolic Bone Disease–Clinical Aspect & Pathogenesis (1886-1891)MODERATORS: Stephen Honig, Stephen Bernstein

SPEAKERS: E Michael Lewiecki, DL Kendler, Kenneth Saag, Aaron Broadwell, C. Tornero


4:30 PM

6:00 PM

4M110 ACR Abstract: Pediatric Rheum–Clinical I: Autoinflammatory Diseases (1892-1897)MODERATORS: Andreas Reiff, Polly Ferguson

SPEAKERS: Florence A. Aeschlimann, Hanna Kim, Fabrizio De Benedetti, Shima Yasin, Sebastiaan Vastert, Esraa M. A. Eloseily


4:30 PM

6:00 PM

4M111 ACR Abstract: RA–Clinical Aspects III: Obesity & Other Comorbidities (1898-1903)MODERATORS John M. Davis III, Kenneth C. Kalunian

SPEAKERS: Stefano Alivernini, Mihir D. Wechalekar, Kerri Ford, Samina A. Turk, Jon T. Giles, Lydia Ho Pui Tam


4:30 PM

6:00 PM

4M112 ACR Abstract: RA–SM Molecules, Biologics & Gene Ther II: Trials Therapy (1904-1909)MODERATORS: Mark C. Genovese, Ernest Choy

SPEAKERS: Gerd R. Burmester, Joel Kremer, Vibeke Strand, Yoshiya Tanaka, Carter Thorne, Mark C. Genovese

1.5 Clinical Science Hall B1

4:30 PM

6:00 PM

4M113 ACR Abstract: SLE–Clinical & Treatment III: Biomarkers (1916-1921)MODERATORS: Maureen A. McMahon, Jorge Sanchez-Guerrero

SPEAKERS: Jenna Thomason, Yasser M El-Sherbiny, Alfred Kim, Chaim Putterman, Vikas Gupta, Samar Soliman


4:30 PM

6:00 PM

4M114 ACR Abstract: Spondyloarthropathies & Psoriatic Arthritis–Pathogenesis, Etiology (1910-1915)MODERATORS: Judith Smith, Jose U. Scher

SPEAKERS: Tri Tran, M. Arifur Rahman, Emmerik F.A. Leijten, Tejpal Gill, Zoya Qaiyum, Karlijn Debusschere

1.5 Basic Science 9

4:30 PM

6:00 PM

4M115 ACR Abstract: Systemic Sclerosis, Fibrosing Syns & Raynaud's–Basic Science I (1922-1927)MODERATORS: Oliver Distler, Carol A. Feghali-Bostwick

SPEAKERS: Shervin Assassi, Sokratis Apostolidis, Rosebeth Kagwiria, Ariella Zehender, Mara Stellato, Tomoya Watanabe

1.5 Basic Science 10

4:30 PM

6:00 PM

4M116 ACR: Mechanisms of Cell Signaling in BoneMODERATORS: Mary Nakamura, Ellen M. Gravallese

SPEAKERS: Julia Charles, Roberto Pacifici, Mitchell B. Schaffler


39

STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

4M117 ACR: Science of Novel ImmunotherapyMODERATORS: Gregg J. Silverman, Cong-Qiu Chu

SPEAKERS: Dennis Carson, Michael Milone


4:30 PM

6:00 PM

4M118 ACR: Thieves' Market: Show Me Your Best CasesMODERATORS: Seth Berney, Mathilde H Pioro

SPEAKERS: Ariane Barbacki, Marc Plier, Nadine Mbuyi, Tamara Dahhan, Evan Mulvihill, Shivani Garg


Training, Tech Med

20 A

4:30 PM

6:00 PM

4M119 ACR: Vasculitis WannabesMODERATORS: Aman Sharma, Eric J. Gapud

SPEAKERS: Eamonn S. Molloy, Jane H. Buckner, Leslie T. Cooper Jr.

1.5 Clinical Practice 20 D

4:30 PM

6:00 PM

4M120 ACR/ARHP Abstract: Epidemiology & Public Health: Prevention, Recognition, Treatment(1862-1867)MODERATORS: Michael P. LaValley, Julia F Simard

SPEAKERS: Candace H. Feldman, Bing Lu, Rishi J. Desai, S. Reza Jafarzadeh, Hsu-Chih Chien, Louise Thoma


4:30 PM

6:00 PM

4M121 ARHP Abstract: Education/Community Programs (1856-1861)MODERATORS: Kamil E. Barbour, David Williams

SPEAKERS: Elizabeth Soto-Cardona, Teresa J. Brady, Barbara Slusher, Benjamin J Smith, Susan J. Blalock, Priscilla Toral


4:30 PM

6:00 PM

4M122 ARHP: Cannabis in Society & Medical PracticeMODERATOR: Leonard H. Sigal

SPEAKERS: Rosalie Pacula, Daniele Piomelli

1.5 Clinical Practice Ethics, Pain Management

5 B

4:30 PM

6:00 PM

4M123 ARHP: If the Shoe Fits: Footwear Interventions for Arthritis Foot PainMODERATOR: Marian T. Hannan

SPEAKERS: Hylton Menz, Keith Rome , Sarah Stewart


11 A

4:30 PM

6:00 PM

4M124 MTP: 049 – Adult Inflammatory Myopathy $SPEAKER: Frederick W Miller



4:30 PM

6:00 PM

4M125 MTP: 050 – Ankylosing Spondylitis: Disease Modification $SPEAKER: Atul A. Deodhar


4:30 PM

6:00 PM

4M126 MTP: 051 – Antiphospholipid Syndrome $SPEAKER: David P. D’Cruz

1.5 Clinical Practice Patient Safety Hilton – Indigo BR C

STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

4M127 MTP: 053 – IgG4-Related Disease $SPEAKER: John H. Stone



4:30 PM

6:00 PM

4M128 MTP: 054 – Infections with Biologics $SPEAKER: Arthur Kavanaugh

1.5 Clinical Practice Patient Safety Hilton – Indigo BR H

4:30 PM

6:00 PM

4M129 MTP: 055 – Management of Difficult Raynaud's & Digital Ischemia $SPEAKER: Thomas A. Medsger Jr.

1.5 Clinical Practice Patient Safety Hilton – Indigo 202 A

4:30 PM

6:00 PM

4M130 MTP: 056 – Safety of Drugs Used to Treat RA $SPEAKER: Eric M. Ruderman

1.5 Clinical Practice Patient Safety Hilton – Indigo 202 B

4:30 PM

6:00 PM

4M131 MTP: 057 – SLE: Novel Treatments – How to Treat SLE $SPEAKER: Richard Furie


4:30 PM

6:00 PM

4M132 MTP: 058 – Systemic Sclerosis: Disease Staging & Subsetting in Clinical Practice $SPEAKER: Laura K. Hummers


TUESDAYN O V E M B E R 7 , 2 0 1 7




Poster Session C and Poster Tours9:00 am – 11:00 am



Innovation Theater A10:30 am – 11:15 am12:30 pm – 1:15 pm

Innovation Theater B11:30 am – 12:15 pm1:30 pm – 2:15 pm

ACR Plenary Session III11:00 am - 12:30 pm





43

STARTTIME

ENDTIME


CMECREDITS


ROOM

Tuesday, Nov. 7 Scientific Sessions


7:30 AM

8:30 AM

5T001 ACR: EULAR/ACR Classification Criteria Update for SLEMODERATORS: David Wofsy, Thomas Dorner

SPEAKERS: Martin Aringer, Sindhu Johnson, Karen H. Costenbader

1 Clinical Science Patient Safety 6 C

7:30 AM

8:30 AM

5T002 ACR: Mentorship for the Next Generation of Rheums: Current State & Next StepsMODERATORS: Jeffrey A. Sparks, Michael J. Ombrello

SPEAKER: Alexis Ogdie, Peter Nigrovic

1 Basic Science Fellows-in-Training

5 B

7:30 AM

8:30 AM

5T003 ACR: Neutrophils as Players & Targets in Systemic Rheumatic DiseasesMODERATOR: Jane E. Salmon

SPEAKER: Mariana Kaplan


7:30 AM

8:30 AM

5T004 ACR: Oscar S. Gluck, MD Memorial Lecture: Parathyroid Hormone: Builder & Destroyer of BoneMODERATOR: Michael J. Maricic

SPEAKER: Henry M. Kronenberg

1 Basic Science 25 A

7:30 AM

8:30 AM

5T005 ACR: Philip Hench, MD Memorial Lecture: ANCA-Associated Vasculitis Diagnosis & TreatmentMODERATOR: Niall Roche

SPEAKER: J. Charles Jennette


7:30 AM

8:30 AM

5T006 ARHP: Engaging with Community Organizations to Promote Physical Activity InterventionsMODERATOR: Leigh F. Callahan

SPEAKER: Yvonne M. Golightly, Kirsten R. Ambrose

1 Clinical Practice Patient Safety 10

7:30 AM

8:30 AM

5T007 ARHP: Immunology Boot Camp III: Principles of Immunology to Treatment DecisionsMODERATOR: Susan Chrostowski

SPEAKER: Troy R. Torgerson, Sandro Perazzio


7:30 AM

8:30 AM

5T008 ARHP: JIA Gait Assessment: What Does a Child's Movement Tell You?MODERATOR: Catherine A. McAuley

SPEAKER: Iris Davidson

1 Clinical Practice Pediatrics 9

7:30 AM

9:00 AM

5T009 ARHP: Death & Devastation: The Effect on Care ProvidersMODERATOR: Leonard H. Sigal

SPEAKER: Marian R. Stuart

1.5 Clinical Science Fellows-in-Training

11 B

STARTTIME

ENDTIME


CMECREDITS


ROOM



7:45 AM

9:15 AM

5T010 MTP: 059 – Controversies with Vitamin D use for Bone Health $SPEAKER: Chad Deal


7:45 AM

9:15 AM

5T011 MTP: 060 – Fibromyalgia 2017: Update on Management $SPEAKER: Daniel J. Clauw



7:45 AM

9:15 AM

5T012 MTP: 061 – Giant Cell Arteritis in 2017: Diagnosis & Management $SPEAKER: Eric L. Matteson



7:45 AM

9:15 AM

5T013 MTP: 062 – Juvenile Dermatomyositis $SPEAKER: Angela B. Robinson



7:45 AM

9:15 AM

5T014 MTP: 063 – Myopathy: Issues in Diagnosis & Treatment $SPEAKER: Mary E. Cronin

1.5 Clinical Practice Hilton – Indigo BR E

7:45 AM

9:15 AM

5T015 MTP: 064 – Non-surgical Treatments for Osteoarthritis $SPEAKER: David T. Felson

1.5 Clinical Practice Hilton – Indigo BR H

7:45 AM

9:15 AM

5T016 MTP: 065 – Reactive Arthritis: An Update $SPEAKER: Siba P. Raychaudhuri



7:45 AM

9:15 AM

5T017 MTP: 066 – RA: Biological Agents $SPEAKER: Stanley B Cohen


Patient Safety


7:45 AM

9:15 AM

5T018 MTP: 067 – Staticial Pearls for improving your Grants $SPEAKER: Elena Losina



7:45 AM

9:15 AM

5T019 MTP: 068 – SLE: Difficult to Treat SLE $SPEAKER: Eliza Chakravarty



7:45 AM

9:45 AM

5T020 Workshop: 226 – Advanced MSUS: Image Optimization & Pathology Recognition $SPEAKERS: Jay B. Higgs, Catherine Bakewell

2 Clinical Practice Hilton – Aqua Salon D

8:30 AM

10:00 AM

5T021 ACR: E-Learning Methods & Educational Technology in Rheumatology EducationMODERATORS: Laura E. Ray, Rosemary G. Peterson

SPEAKERS: Michal Cidon, Kristen Hayward, Bethany A. Marston

1.5 Clinical Science Educator, Pediatrics, Tech

Med

23 A

45

STARTTIME

ENDTIME


CMECREDITS


ROOM



8:30 AM

10:00 AM

5T022 ACR: Management of OA: Beyond the GuidelinesMODERATOR: C. Kent Kwoh

SPEAKERS: Steven B. Abramson, Timothy E. McAlindon


8:30 AM

10:00 AM

5T023 ACR: MOC UpdateSPEAKER: Carol A. Langford

1.5 Clinical Practice 32 B

8:30 AM

10:00 AM

5T024 ACR: RA & SLE Molecular & Cellular Disease Deconstruction: AMP Insights & ProgressMODERATORS: Jennifer H. Anolik, Michael B. BrennerSPEAKERS: Jennifer H. Anolik, Michael B. Brenner, Soumya Raychaudhuri, Jill P. Buyon, Betty Diamond, Nir Hacohen, Judith A. James, Thomas Tuschl

1.5 Basic Science 28 A-E

8:30 AM

10:00 AM

5T025 ACR: The Effects of Medications & Hormones Across the Lifespan: Pills or Potions?MODERATORS: Rebecca L. Manno

SPEAKERS: Megan E. B. Clowse, Adrian Dobs, Lisa A. Mandl

1.5 Clinical Science Patient Safety 33 C

8:30 AM

10:00 AM

5T026 ACR: Timely Topics in SLEMODERATORS: Grant Hughes, Jenna Thomason

SPEAKERS: Susan Manzi, Terry Gernsheimer, Ronald F van Vollenhoven

1.5 Clinical Science Hall B1

8:30 AM

10:00 AM

5T027 ACR/ARHP: Weekend Warriors: Sports Medicine for RheumatologyMODERATORS: Gurjit S. Kaeley, Catherine A. McAuley

SPEAKERS: Andrew Concoff, Jean Gillies, Alex Scott


9

8:30 AM

10:30 AM

5T028 ACR: Pan-American Guidelines on Rheumatic Diseases Update. Presented by PANLARSPEAKERS: Carlo V Caballero-Uribe Sr., Enrique R Soriano, Mario Cardiel, Wilson Bautista


9:00 AM

10:00 AM

5T029 ACR: ACR Recommendations for RA Disease Activity and Functional Status MeasuresMODERATOR: John Fitzgerald

SPEAKERS: Bryant R. England, Claire Barber, Kaleb Michaud

1 Clinical Science Patient Safety 20 D

9:00 AM

10:00 AM

5T030 ACR: Immunology Update: Therapeutic Targeting of T Cell SubsetsMODERATOR: Gregg J. Silverman

SPEAKERS: R. John Looney


STARTTIME

ENDTIME


CMECREDITS


ROOM



9:00 AM

10:00 AM

5T031 ACR: Intro to Advocacy: First Steps, Social Media & TechnologyMODERATORS: Angus Worthing, Elizabeth Blair Solow

SPEAKERS: Tim Hutchinson


Educator, Fellows-in-

Training, Patient Safety,

Practice Manager

5 B

9:00 AM

10:00 AM

5T032 ACR: Performance-Based Contracting: Emerging Issues & ConsiderationsSPEAKERS: Greg Mertz


Practice Manager

6 D

9:00 AM

10:00 AM

5T033 ARHP: Daltroy Memorial Lecture: Happiness & the Immune SystemMODERATORS: Christine A. Stamatos, Karen L. Smarr

SPEAKERS: Sarah Pressman


11 B

9:00 AM

10:00 AM

5T034 ARHP: Understanding the “Who” & “How” in Your Data: Moderators & Mediators in ResearchMODERATORS: Susan L. Murphy, Jasvinder A. Singh

SPEAKERS: Stephanie Moser

1 Clinical Science 10

9:00 AM

11:00 AM

5T035 Posters: ACR/ARHP Poster Session C and Poster Tours



10:00 AM

2:30 PM

5T036 Exhibits

Exhibit Hall Morning Snack Break (10:00 AM)

0 Exhibit Hall F-G

10:30 AM

11:15 AM

5T037 Exhibits: Innovation Theater A 0 Exhibit Hall F-G

10:30 AM

12:30 PM

5T038 Workshop: 227 – Dermatopathology of Rheumatic Diseases $SPEAKER: Daniel Miller


10:30 AM

12:30 PM

5T039 Workshop: 228 – Integrating Disease Activity Measurement Into Any Clinical Practice $SPEAKERS: Arthur M. Mandelin II, Sharon Tymkiw

2 Clinical Practice Patient Safety Hilton – Aqua Salon E

10:30 AM

12:30 PM

5T040 Workshop: 229 – Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice $SPEAKERS: Philip G. Conaghan, Mikkel Østergaard


47

STARTTIME

ENDTIME


CMECREDITS


ROOM



11:00 AM

12:00 PM

5T041 ACR: Anatomy for the Clinician III: Shoulder Pain: Practical Anatomy & EvaluationMODERATORS: Gurjit S. Kaeley, Jasvinder A. Singh

SPEAKERS: Kenneth S. O’Rourke, Carlo Martinoli


Training, Pain Management

30 E

11:00 AM

12:00 PM

5T042 ACR: Development of the Synovial Joint: Implications for ArthritisMODERATOR: Dennis McGonagle

SPEAKER: Maurizio Pacifici

1 Basic Science 5 B

11:00 AM

12:00 PM

5T043 ACR: Microbiota Alteration in Juvenile Idiopathic ArthritisMODERATOR: Melissa L. Mannion

SPEAKERS: Daniel B. Horton, Matthew L. Stoll

1 Clinical Science Pediatrics 11 A

11:00 AM

12:00 PM

5T044 ACR: Recent Advances in Asia Pacific League of Association for Rheumatology. Presented by APLARMODERATOR: Yeong Wook Song

SPEAKERS: Kazuhiko Yamamoto, Jang-Soo Chun, Zhanguo Li


11:00 AM

12:00 PM

5T045 ACR: Solving Problems in Rheumatology & Cognitive ScienceMODERATOR: Swamy Venuturupalli

SPEAKER: Kyu Rhee

1 Clinical Science Fellows-in-Training, Tech

Med

20 A

11:00 AM

12:30 PM

5T046 ACR Abstract: Plenary Session III (2753-2758)SPEAKERS: Neil Basu, Pierre Charles, Michael D. George, Lindsey A. MacFarlane, Evan Der, Gina A. Montealegre Sanchez

1.5 Hall B1

11:00 AM

12:30 PM

5T047 ACR: Critical Peer Review of Research Manuscripts: A Hands-On Session With ACR Journal EditorsMODERATOR: Marian T. Hannan

SPEAKERS: Richard J. Bucala, Marian T. Hannan, Richard J. Bucala, Marian T. Hannan, Michael P. LaValley, Daniel H. Solomon, Richard J. Bucala, Marian T. Hannan


11:30 AM

12:15 PM

5T048 Exhibits: Innovation Theater B 0 Exhibit Hall F-G

12:30 PM

1:15 PM

5T049 Exhibits: Innovation Theater A 0 Exhibit Hall F-G

STARTTIME

ENDTIME


CMECREDITS


ROOM



12:30 PM

2:00 PM

5T050 ACR: 2017 CARE: MOC Sessions 3 of 3: Images in RheumatologyMODERATOR: Allan C. Gelber

SPEAKER: Jonathan S. Hausmann


12:30 PM

2:00 PM

5T051 ACR: Autoimmunity & CancerMODERATORS: Julie J. Paik, Peter A. Valen

SPEAKERS: Ami A. Shah, Laura Cappelli


12:45 PM

2:15 PM

5T052 MTP: 069 – Axial Spondyloarthritis/Ankylosing Spondylitis $SPEAKER: Liron Caplan

1.5 Clinical Practice Patient Safety Hilton – Indigo BR A

12:45 PM

2:15 PM

5T053 MTP: 070 – Biomechanical Interventions for Managing Orthoarthritis $SPEAKER: Kelly D. Krohn


12:45 PM

2:15 PM

5T054 MTP: 071 – Management of Patients with Hepatitis C & Rheumatic Diseases $SPEAKER: Timothy B. Niewold



12:45 PM

2:15 PM

5T055 MTP: 072 – Pediatric SLE $SPEAKER: Marisa S. Klein-Gitelman


Patient Safety, Pediatrics


12:45 PM

2:15 PM

5T056 MTP: 073 – Psoriatic Arthritis $SPEAKER: Jessica A. Walsh



12:45 PM

2:15 PM

5T057 MTP: 074 – Pulmonary Hypertension in the Rheumatic Diseases $SPEAKER: Dinesh Khanna

1.5 Patient Safety Hilton – Indigo BR H

12:45 PM

2:15 PM

5T058 MTP: 075 – Scleroderma Mimics $SPEAKER: Virginia D. Steen



12:45 PM

2:15 PM

5T059 MTP: 076 – Still's Disease & Autoinflammatory Syndromes $SPEAKER: Petros Efthimiou


12:45 PM

2:15 PM

5T060 MTP: 077 – SLE: Novel Treatments $SPEAKER: Susan Manzi


12:45 PM

2:15 PM

5T061 MTP: 078 – Vaccinations for Patients on Biologic Therapies $SPEAKER: Jeffrey R. Curtis

1.5 Clinical Practice Ethics, Fellows-in-Training,

Patient Safety


49

STARTTIME

ENDTIME


CMECREDITS


ROOM



1:00 PM

2:00 PM

5T062 ACR: Genetics of Chronic PainMODERATOR: Teresa K. Tarrant

SPEAKER: William Maixner

1 Basic Science Pain Management

5 B

1:00 PM

2:00 PM

5T063 ACR: Molecular Basis of InflammationMODERATOR: Mary Nakamura

SPEAKER: Hugh Rosen

1 Basic Science 24 A

1:00 PM

2:00 PM

5T064 ACR: Treatment of Psoriatic Arthritis: A New ACR/NPF Clinical GuidelineMODERATOS: Dafna D Gladman, M. Elaine Husni

SPEAKERS: Alexis Ogdie, Jasvinder A. Singh, Evan Siegel

1 Clinical Practice Patient Safety 30 E

1:00 PM

2:00 PM

5T065 Study Group: ACR-EULAR SynovialSPEAKERS: Jennifer H. Anolik, Michael B. Brenner, Andrew Filer, Arthur M. Mandelin II, Stephen Kelly, David L. Boyle, Ellen M. Gravallese, Costantino Pitzalis, Bernard R. Lauwerys


1:00 PM

2:00 PM

5T066 Study Group: Behçet's DiseaseSPEAKERS: Haner Direskeneli, Amr H Sawalha, Alfred Mahr, Dennis McGonagle


1:00 PM

2:00 PM

5T067 Study Group: Complementary & Integrative Medicine for Rheumatic DiseasesSPEAKERS: Nisha J. Manek, George Munoz, Randy Horwitz, Jose Antonio Pando

0 Clinical Science 33 C

1:00 PM

2:00 PM

5T068 Study Group: High-Resolution Peripheral Quantitative Computed Tomography: Outcome Tool in RheumSPEAKERS: Lai-Shan Tam, Sarah Manske, Ellen-Margrethe Hauge, Hubert Marotte, Xiaojuan Li, Stephanie Finzel


1:00 PM

2:00 PM

5T069 Study Group: Neuroendocrine Immunology: New Concepts to Reduce Glucocorticoid ToxicitySPEAKERS: Georg Pongratz, Richard Imrich , Ricke Alten, Maurizo Cutolo


1:00 PM

2:00 PM

5T070 Study Group: OsteoarthritisSPEAKERS: Anne-Marie Malfait


1:00 PM

2:00 PM

5T071 Study Group: Patient Research PartnersSPEAKERS: Jennifer R. Horonjeff, Kaleb Michaud


1:00 PM

2:00 PM

5T072 Study Group: Pediatric Musculoskeletal Exam TeachingSPEAKERS: Jay Mehta, Megan L. Curran


STARTTIME

ENDTIME


CMECREDITS


ROOM



1:00 PM

2:00 PM

5T073 Study Group: Polymyalgia Rheumatica (PMA)/Giant Cell Arteritis (GCA)SPEAKERS: Eric L. Matteson, Bhaskar Dasgupta


1:00 PM

2:00 PM

5T074 Study Group: Relapsing PolychondritisSPEAKER: Marcela A. Ferrada


1:15 PM

3:15 PM

5T075 Workshop: 230 – Joint Injection Techniques $SPEAKERS: Atul A. Deodhar, Kenneth S. O’Rourke

2 Clinical Practice Hilton – Aqua Salon E

1:15 PM

3:15 PM

5T076 Workshop: 231 – MSUS Board Review $SPEAKERS: Gurjit S. Kaeley, Johannes Roth, Wolfgang A. Schmidt



1:15 PM

3:15 PM

5T077 Workshop: 232 – Osteoporosis: DEXA & Clinical Risk Factors: New Fracture Risk Algorithm $SPEAKER: Stuart L. Silverman


1:15 PM

3:15 PM

5T078 Workshop: 233 – Tai Chi, Qigong, Feldenkrais, Yoga For Your Practice: Mind Body Practice $SPEAKER: Mary L. Jurisson s

2 Clinical Practice Patient Safety Hilton – Aqua Salon C

1:30 PM

2:00 PM

5T079 ACR: ACR Business MeetingMODERATOR: Sharad Lakhanpal

SPEAKERS: Paula Marchetta, Eric L. Matteson, Afton L. Hassett, Ellen M. Gravallese, Joan Marie Von Feldt, David I. Daikh


31 C

1:30 PM

2:15 PM

5T080 Exhibits: Innovation Theater B 0 Exhibit Hall F-G

2:30 PM

3:30 PM

5T081 ACR: ILAR Session: How Rheumatologists Are Trained Around the GlobeMODERATOR: Olufemi Adelowo

SPEAKERS: Johannes W.J. Bijlsma, Olufemi Adelowo, Kazuhiko Yamamoto, Carlo V Caballero-Uribe Sr.

1 Clinical Practice Educator 31 C

2:30 PM

3:30 PM

5T082 ACR: TAMs: Master Regulators on Inflammation & AutoimmunityMODERATOR: Gregg J. Silverman

SPEAKER: Greg Lemke

1 Basic Science 5 B

2:30 PM

4:00 PM

5T083 ACR Abstract: Antiphospholipid Syndrome (2759-2764)MODERATOR: Yehuda Shoenfeld , Joan T. Merrill

SPEAKERS: Massimo Radin, Doruk Erkan, Ramadan A. Ali, Nathalie Costedoat-Chalumeau, Andras Perl, Patricia Ruiz-Limon


51

STARTTIME

ENDTIME


CMECREDITS


ROOM



2:30 PM

4:00 PM

5T084 ACR Abstract: Innate Immunity & Rheumatic Disease (2771-2776)MODERATORS: Pui Lee, J. Michelle Kahlenberg

SPEAKERS: Gabriel Mbalaviele, Paul Tsoukas, Keith A. Sikora, Umesh S Deshmukh, Alexandre LE JONCOUR, Suzanne Kafaja


2:30 PM

4:00 PM

5T085 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II (2777-2782)MODERATORS: Liana Fraenkel, Michael Weisman

SPEAKERS: Maria I. Danila, Mark Harrison, A.A. Den Broeder, Liana Fraenkel, Huifeng Yun, Richard W Martin


2:30 PM

4:00 PM

5T086 ACR Abstract: RA–Clinical Aspects IV: Medications & Risk (2783-2788)MODERATORS: Joshua Baker, Grant Cannon

SPEAKERS: Gulsen Ozen, Chi Chi Lau, Sasha Bernatsky, Michael D. George, Kevin Winthrop, Daniel H. Solomon


2:30 PM

4:00 PM

5T087 ACR Abstract: RA–Human Etiology & Pathogenesis I (2789-2794)MODERATOR: Erika H. Noss, Stephanie Standford

SPEAKERS: Shinji Matsuda, Gyrid Nygaard, Linda Johansson, Yusuke Miyazaki, Deepa Hammaker, Joo Youn Lee


2:30 PM

4:00 PM

5T088 ACR Abstract: RA–SM Molecules, Biologics & Gene Ther III: Biosimilars Therapy (2795-2800)MODERATORS: J. Steuart Richards, Eduardo Mysler

SPEAKERS: Dmitrij Kollins, Josef S. Smolen, Arthur Kavanaugh, Stanley B Cohen, Mark C. Genovese, Guro Løvik Goll


2:30 PM

4:00 PM

5T089 ACR Abstract: SLE–Clinical & Treatment IV: Neuropsychiatric DX & Health Economics (2807-2812)MODERATORS: Patricia P. Katz, Peter M. Izmirly

SPEAKERS: Zahi Touma, Erik Anderson, Andrea M. Knight, Ann E. Clarke, Christopher F Bell


2:30 PM

4:00 PM

5T090 ACR Abstract: SLE–Human Etiology & Pathogenesis I (2813-2818)MODERATORS: Jill P. Buyon, Mary K. Crow

SPEAKERS: Ashira Blazer, Jennie Hamilton, Robert M. Clancy, Md Yuzaiful Md Yusof, Gudny Ella Thorlacius, Michelle Catalina


STARTTIME

ENDTIME


CMECREDITS


ROOM



2:30 PM

4:00 PM

5T091 ACR Abstract: Spondyloarthropathies & Psoriatic Arthritis–Clinical & Treatment III (2801-2806)MODERATORS: Walter P. Maksymowych, Laura C Coates

SPEAKERS: Leonieke van Mens, Walter P. Maksymowych, Joachim Sieper, Yao-Fan Fang, Anthony So, Alexandre Sepriano


2:30 PM

4:00 PM

5T092 ACR: Building a Career as a Clinician Educator: Tools for SuccessMODERATORS: Grant Hughes, Mathilde H Pioro

SPEAKERS: Karen Hauer, Meridale Baggett, Jess Mandel


2:30 PM

4:00 PM

5T093 ACR: Emerging Viral Arthritides: Chikungunya, Dengue & ZikaMODERATORS: Aman Sharma, Robert D Inman

SPEAKERS: Arvind Chopra, Rohini Handa, Leonard H. Calabrese

1.5 Clinical Science Patient Safety Hall B1

2:30 PM

4:00 PM

5T094 ACR: Sarcoidosis-Update on Pathogenesis, Patient Evaluation & TreatmentMODERATORS: Peter A. Valen, Anna Shmagel

SPEAKERS: Daniel A. Culver, Marc Judson, Robert Baughman


2:30 PM

4:00 PM

5T095 ACR/ARHP: Phenotyping Hip & Knee OA: Toward Better Clinical Care & Patient OutcomesMODERATORS: Amanda Nelson, Jeffrey B. Driban

SPEAKERS: Ali Mobasheri, David Hunter


2:30 PM

4:00 PM

5T096 ARHP Abstract: Rehabilitation Science (2765-2770)MODERATORS: Dina L. Jones, Susan L. Murphy

SPEAKERS: Hylton Menz, Kelli Allen, Hiral Master, Adam P. Goode, Alix St-Aubin, Pamela Semanik


2:30 PM

4:00 PM

5T097 ARHP: DMARDs & Biologics: What Rheumatology Nurses Should KnowMODERATOR: Stacey Busch

SPEAKER: Jessica Farrell

1.5 Clinical Practice Patient Safety 11 A

2:30 PM

4:00 PM

5T098 ARHP: Orthopedic Management in Pediatric Rheumatology: When to Intervene Surgically?MODERATORS: Iris Davidson, Peter Weiser

SPEAKERS: Sue Maillard, Mark P. Figgie, John Herzenberg

1.5 Clinical Practice Pain Management,

Pediatrics

10

53

STARTTIME

ENDTIME


CMECREDITS


ROOM



2:30 PM

4:00 PM

5T099 ARHP: Osteoporosis: Preventing FracturesMODERATORS: George A. W. Bruyn, Janine Shinn

SPEAKERS: Ralf G. Thiele, George A.W. Bruyn, Lai-Shan Tam

1.5 Clinical Practice 9

4:00 PM

6:00 PM

5T100 Workshop: 234 – Patient MDHAQ/RAPID3 & MD RheuMetric: Tools to Improve Documentation & Outcomes $SPEAKER: Theodore Pincus



4:00 PM

6:00 PM

5T101 Workshop: 235 – Shoulder Pain – Clinical & Ultrasound Assessment $SPEAKERS: Michael J. Battistone, Ami Ben-Artzi, Andrea Barker



4:00 PM

6:00 PM

5T102 Workshop: 236 – Systemic Sclerosis: How to Perform Skin Scores $SPEAKER: Daniel E. Furst



4:30 PM

6:00 PM

5T103 ACR Abstract: Genetics, Genomics & Proteomics (2825-2830)MODERATORS: Betty Tsao, Amr H Sawalha

SPEAKERS: John B. Harley, Soumya Raychaudhuri, Fan Zhang, Naomi I. Maria, Rizi Ai, Joel A.G. van Roon


4:30 PM

6:00 PM

5T104 ACR Abstract: Health Services Research: Cost Drivers in Rheumatic Disease (2831-2836)MODERATORS: Tina D. Mahajan, Virginia D. Steen

SPEAKERS: John Woolcott, A.A. Den Broeder, Savannah R. Smith, Nina Mars, Anne-Christine Rat, Nan Li


4:30 PM

6:00 PM

5T105 ACR Abstract: Infection-related Rheumatic Disease (2837-2842)MODERATORS: Asena Bahce-Altuntas, Raquel Cuchacovich

SPEAKERS: Aileen Chang, Stanley J. Naides, Rachel M. Wolfe, Mary Louise Fowler, Soledad Retamozo, Alain Saraux


4:30 PM

6:00 PM

5T106 ACR Abstract: Metabolic & Crystal Arthropathies I: Gout Risks and Mortality (2843-2848)MODERATORS: Theodore R. Fields, John Fitzgerald

SPEAKERS: Nicola Dalbeth, MaryAnn Zhang, Lisa K. Stamp, Ana Beatriz Vargas-Santos, Abhishek Abhishek, Ted R. Mikuls


STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

5T107 ACR Abstract: Orthopedics, Low Back Pain & Rehabilitation (2849-2854)MODERATORS: M. Elaine Husni, Lisa A. Mandl

SPEAKERS: Raveendhara R. Bannuru, Maria Greenwald, Aladdin Shadyab, Ernest Vina, Lisa A. Mandl, Christian Ray Smith


4:30 PM

6:00 PM

5T108 ACR Abstract: Pediatric Rheum–Clinical II: Juvenile Arthritis (2855-2860)MODERATORS: Patricia Vega-Fernandez, Pamela F. Weiss

SPEAKERS: Hermine I. Brunner, Navita L. Mallalieu, Nuria Vegas-Revenga, Daniel J Lovell, Alessandro Consolaro, Maria M. Katsicas


4:30 PM

6:00 PM

5T109 ACR Abstract: RA–Clinical Aspects V: Predicting Treatment Response (2861-2865)MODERATORS: Iris Navarro-Millán, Amy C. Cannella

SPEAKERS: Vibeke Norvang, Craig Wiesenhutter, Liam O’Neil, Paul Studenic, Carl Orr


4:30 PM

6:00 PM

5T110 ACR Abstract: RA–SM Molecules, Biologics & Gene Ther IV: Pharmacodynamic Markers (2866-2871)MODERATORS: Peter C. Taylor, Alan K Matsumoto

SPEAKERS: Paul Emery, Vikas Gupta, O Jabado, Katerina Chatzidionysiou, Iain B. McInnes, Günter Steiner


4:30 PM

6:00 PM

5T111 ACR Abstract: Sjögren's Syndrome II: Pathogenesis, Autoantibodies & T-Cells (2872-2877)MODERATORS: Eugene St. Clair, Donald Bloch

SPEAKERS: Sofie L.M. Blokland, Hiroyuki Takahashi, Saviana Gandolfo, Judith A. James, Alan N. Baer, Patrizia Fasching


4:30 PM

6:00 PM

5T112 ACR Abstract: Spondyloarthropathies & Psoriatic Arthritis–Clinical & Treatment IV (2878-2883)MODERATOR: Eric M. Ruderman, Liron Caplan

SPEAKERS: Atul A. Deodhar, Barbara Finck, Runsheng Wang, Philippe Carron, Jing Liu, María Paz Martínez-Vidal


4:30 PM

6:00 PM

5T113 ACR Abstract: Systemic Sclerosis, Fibrosing Syns & Raynaud's–Clinical & THR II (2884-2889)MODERATORS: Flavia V. Castelino, Murray Baron

SPEAKERS: Robert F. Spiera, Sakir Ahmed, Hans-Peter Brezinschek, Hiroyuki Nakamura, Benjamin Chaigne, Alberto Sulli


4:30 PM

6:00 PM

5T114 ACR Abstract: ACR Late-breaking Abstract Session

1.5 Hall B1

55

STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

5T115 ACR: Auto-inflammatory Syndromes from Bench to Bedside: Genetics, Recognition & TreatmentMODERATORS: Petros Efthimiou, Jonathan S. Hausmann

SPEAKERS: Daniel L. Kastner, John J. Cush


4:30 PM

6:00 PM

5T116 ACR: Functional Properties of ACPA & Related AntibodiesMODERATOR: Kevin D. Deane

SPEAKERS: Tom W.J. Huizinga, Georg Schett, Camilla Svensson

1.5 Basic Science Pain Management

5 B

4:30 PM

6:00 PM

5T117 ACR: Hot Topics in MyositisMODERATORS: Andrew Mammen, Gregory Gardner

SPEAKERS: Rohit Aggarwal, Eleni Tiniakou, Paul F. Dellaripa

1.5 Clinical Practice Patient Safety 20 D

4:30 PM

6:00 PM

5T118 ACR/ARHP: Are We Missing Hypermobility Syndrome in Our Patients?MODERATORS: Irene J. Tan, Heather Finlayson

SPEAKERS: Eric Gall, Peter Byers, Corey Woldenberg


24 A

4:30 PM

6:00 PM

5T119 ARHP Abstract: Exemplary Abstracts (2819-2824)MODERATORS: Rebecca J. Cleveland, Kaleb Michaud

SPEAKERS: Divya Narayanan, Teresa Aberle, Christopher Hawke, Dina L. Jones, Christine Pellegrini, Teresa A. Lillis


4:30 PM

6:00 PM

5T120 ARHP: National Strategies for Addressing PainMODERATOR: James Udell

SPEAKERS: Vanila Singh, Linda Porter, Charles G. Helmick


9

4:30 PM

6:00 PM

5T121 ARHP: The Role of Clinical Pharmacy Specialists in a Pediatric Clinic $MODERATOR: Scott Lieberman

SPEAKERS: Jessica Lynton, Polly Ferguson, Alex Mersch

1.5 Clinical Practice Patient Safety, Pediatrics

10

4:30 PM

6:00 PM

5T122 MTP: 079 – Behçet's Syndrome $SPEAKER: Kenneth Calamia


4:30 PM

6:00 PM

5T123 MTP: 080 – Difficult-to-treat-JIA: What else is in our bag of tricks? $SPEAKER: Ginger Janow



4:30 PM

6:00 PM

5T124 MTP: 082 – Immunodeficiency Syndromes $SPEAKER: Marc Riedl



STARTTIME

ENDTIME


CMECREDITS


ROOM



4:30 PM

6:00 PM

5T125 MTP: 083 – Neuropsychiatric Lupus $SPEAKER: W. Winn Chatham

1.5 Clinical Practice Hilton – Indigo BR E

4:30 PM

6:00 PM

5T126 MTP: 084 – RA: Biological Agents $SPEAKER: Stanley B Cohen


Patient Safety


4:30 PM

6:00 PM

5T127 MTP: 085 – Spondylarthropathy: An Update $SPEAKER: Christopher T. Ritchlin



4:30 PM

6:00 PM

5T128 MTP: 086 – SLE: Difficult to Treat SLE $SPEAKER: Eliza Chakravarty


4:30 PM

6:00 PM

5T129 MTP: 087 – Vasculitis: Factors That Influence Disease Pattern $

SPEAKER: Kenneth J. Warrington s



6:30 PM

9:30 PM

5T130 Exhibits: Industry-Supported Symposia 0 See page 66 or the Annual


symposia.

WEDNESDAYN O V E M B E R 8 , 2 0 1 7



Abstract Sessions9:00 am – 10:30 am11:00 am – 12:30 pm


59

STARTTIME

ENDTIME


CMECREDITS


ROOM

Wednesday, Nov. 8 Scientific Sessions

7:30 AM

8:30 AM

6W001 ACR: All Roads Lead to FibrosisMODERATOR: John Varga

SPEAKERS: Jörg Distler, Oliver Distler

1 Basic Science Fellows-in-Training, Pediatrics

24 A

7:30 AM

8:30 AM

6W002 ACR: Rheumatology Roundup: Highlights From the 2017 ACR/ARHP Annual MeetingMODERATOR: Richard F. Loeser

SPEAKERS: John J. Cush, Arthur Kavanaugh


7:30 AM

8:30 AM

6W003 ACR: Top 10 Lessons Learned Using Virtual Reality for Pain ManagementMODERATORS: Swamy Venuturupalli, Emma (Chen) Tang

SPEAKER: Brennan Spiegel

1 Clinical Science Pain Management,

Tech Med

5 B

7:30 AM

9:00 AM

6W004 ACR: Innovative Research: A Rheumatology Research Foundation Special SessionMODERATOR: Bryce A. Binstadt

SPEAKERS: Joseph E. Craft, Timothy B. Niewold, Inez Rogatsky

1.5 Basic Science 28 A-E

8:00 AM

9:00 AM

6W005 ACR: Understanding Chronic Pain Mechanisms through Advanced NeuroimagingMODERATOR: Daniel J. Clauw

SPEAKER: Irene Tracey

1 Basic Science Pain Management

33 C

9:00 AM

10:00 AM

6W006 ARHP: Rheumatology 9-1-1: Recognizing Medical EmergenciesMODERATOR: Aleksander Lenert

SPEAKER: Bharat Kumar

1 Clinical Practice Patient Safety 11 A

9:00 AM

10:30 AM

6W007 ACR Abstract: Health Services Research: Methods & Technology in Care & Research (2890-2895)MODERATOR: Charles G. Helmick

SPEAKERS: Milena Gianfrancesco, E Alemao, Jiha Lee, Grant Cannon, Patrick R. Wood, Kaveh Ardalan


9:00 AM

10:30 AM

6W008 ACR Abstract: Metabolic & Crystal Arthropathies II: Inflammation & Metabolism (2896-2901)MODERATORS: Robert Terkeltaub, Robert T. Keenan

SPEAKERS: Nicola Dalbeth, Tony R. Merriman, Owen M. Woodward, Estrella Garcia Gonzalez, Geraldine M. McCarthy, Anthony M. Reginato


STARTTIME

ENDTIME


CMECREDITS


ROOM



9:00 AM

10:30 AM

6W009 ACR Abstract: Miscellaneous Rheumatic & Inflammatory Diseases II (2902-2907)MODERATORS: Apostolos Kontzias, Lee S. Shapiro

SPEAKERS: Laura Cappelli, Mitsuhiro Akiyama, Deborah Puyraimond-Zemmour, Yoon-Jeong Oh, Dominick Sudano, Eduardo Martín Nares


9:00 AM

10:30 AM

6W010 ACR Abstract: RA–Clinical Aspects VI: Comorbidities of RA (2908-2913)MODERATORS: Susan Lee, Rebecca L. Manno

SPEAKERS: Bindee Kuriya, Ruediger Mueller, Pascal Zufferey, Mark Edward Hall, Andrew Schrepf, Jon T. Giles


9:00 AM

10:30 AM

6W011 ACR Abstract: RA–Human Etiology & Pathogenesis II (2914-2919)MODERATOR: Maripat Corr, David L. Boyle

SPEAKERS: M. Kristen Demoruelle, Bryant R. England, Emma de Moel, Mary Bach, Lindsay B. Kelmenson, Vijay Joshua


9:00 AM

10:30 AM

6W012 ACR Abstract: SLE–Clinical & Treatment V: Longterm Outcomes (2920-2925)MODERATOR: Ian N. Bruce, Meenakshi Jolly

SPEAKERS: Sara K. Tedeschi, April Jorge, Christine Peschken, Murray Urowitz, Guillermo J. Pons-Estel, Ann E. Clarke


9:00 AM

10:30 AM

6W013 ACR Abstract: Systemic Sclerosis, Fibrosing Syns & Raynaud's–Basic Science II (2926-2931)MODERATORS: Francesco Boin, Shervin Assassi

SPEAKERS: W. Alexander Stinson, Minghua Wu, Debomita Chakraborty, Chih-Wei Chen, Pravitt Gourh, Bhaven K. Mehta

1.5 Basic Science 10

9:00 AM

10:30 AM

6W014 ACR Abstract: Vasculitis III: Pathogenesis (2932-2937)MODERATORS: Paul A. Monach, Sarah Mackie

SPEAKERS: Jérôme Hadjadj, Cornelia M. Weyand, Cornelia M. Weyand, Rennie L. Rhee, Wayel H. Abdulahad, Chisato Shimizu


9:00 AM

10:30 AM

6W015 ACR: Evolving Concepts in FibromyalgiaMODERATORS: Lan Chen, Arthur Weinstein

SPEAKERS: Daniel J. Clauw, Marina López-Solà, Brian Walitt


30 E

9:00 AM

10:30 AM

6W016 ACR: How to Find the Right Grant at the Right Time: Meet the NIH & Foundation LeadersMODERATOR: Alfred Kim

SPEAKERS: Jeffrey A. Sparks, John Peyman, Marie Mancini, Su-Yau Mao, Michael Siegel, Joyce Kullman, Hermine I. Brunner, Yan Wang, Steven Taylor, Helene Belisle, Robert J. Riggs, Guy Eakin


61

STARTTIME

ENDTIME


CMECREDITS


ROOM


9:00 AM

10:30 AM

6W017 ACR: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special SessionMODERATOR: Lisa Criscione-Schreiber

SPEAKERS: Karen Law, Maria Dall’Era, Eli Miloslavsky


Training

24 A

9:00 AM

10:30 AM

6W018 ACR/ARHP Abstract: Pediatric Rheumatology–Clinical (2992-2997)MODERATORS: Donald P. Goldsmith, John F. Bohnsack

SPEAKERS: Sabrina Gmuca, Daniel Whittingslow, Lisa Buckley, Nancy Delnay, Jamie Lai, Nicole Tennermann


9:00 AM

10:30 AM

6W019 ACR/ARHP: Pain Management in the Pediatric Rheumatology ClinicMODERATOR: Scott Lieberman

SPEAKERS: William Bernal, Cristina Benki

1.5 Clinical Practice Pain Management, Patient Safety,

Pediatrics

5 B

11:00 AM

12:00 PM

6W020 ACR: ACR/EULAR Classification Criteria Update for ANCA-Associated Vasculitides in the Age of ANCAMODERATORS: Peter A. Merkel, Richard Watts

SPEAKERS: Joanna Robson, Cristina Ponte, Peter C. Grayson, Ravi Suppiah

1 Clinical Science Patient Safety 6 A

11:00 AM

12:00 PM

6W021 ACR: Septic Arthritis: Clinical ReviewMODERATORS: Seth Berney, Jonathan S. Hausmann

SPEAKERS: Ziv Paz

1 Clinical Practice Patient Safety 6 D

11:00 AM

12:00 PM

6W022 ARHP: IL1 Mediated Diseases Across the LifespanMODERATORS: Christian Hedrich, Scott Canna

SPEAKERS: Polly Ferguson

1 Clinical Science Patient Safety 11 B

11:00 AM

12:30 PM

6W023 ACR Abstract: Imaging of Rheumatic Diseases II: Focus on RA & SSc (2938-2943)MODERATORS: Mikkel Ostergaard, Ralf G. Thiele

SPEAKERS: Lene Terslev, Fan XIAO, Gaël Mouterde, Jiang Yue, Hanyan Zou, Esther Mossel


11:00 AM

12:30 PM

6W024 ACR Abstract: OA–Clinical Aspects II: Pain & Functional Outcomes (2944-2949)MODERATOR: Philip G. Conaghan, Jonathan Samuels

SPEAKERS: Julie Davis, Timothy E. McAlindon, Jamie E. Collins, Leticia Deveza, C. Kent Kwoh, Dana Mathews


STARTTIME

ENDTIME


CMECREDITS


ROOM



11:00 AM

12:30 PM

6W025 ACR Abstract: Patient Outcomes, Preferences, & Attitudes III (2950-2955)MODERATORS: Alexis Ogdie, Patricia P. Kat

SPEAKERS: Angelo L. Gaffo, Jeffrey R. Curtis, Jennifer N. Stinson, Bhavika Sethi, Graham Macdonald, Susan J. Bartlett

1.5 Clinical Science 30 E

11:00 AM

12:30 PM

6W026 ACR Abstract: Pediatric Rheum–Clinical III: Lupus, Dermatomyositis, Scleroderma (2956-2961)MODERATORS: Stacy P. Ardoin, Mara L. Becker

SPEAKERS: Gabriella Giancane, Amit Saxena, Hermine I. Brunner, Ivan Foeldvari, Kaveh Ardalan, Birgit Nomeland Witczak


11:00 AM

12:30 PM

6W027 ACR Abstract: RA–SM Molecules, Biologics & Gene Ther V: Imaging & Cardiovascular (2962-2967)MODERATORS: Maya H. Buch, Allan Gibofsky

SPEAKERS: Charles Peterfy, Peter C. Taylor, MJ Bergman, Fabiola Atzeni, Michael Nurmohamed, Alexandre Sepriano


11:00 AM

12:30 PM

6W028 ACR Abstract: SLE–Human Etiology & Pathogenesis II (2974-2979)MODERATORS: Andras Perl, Bevra H. Hahn

SPEAKERS: Scott Jenks, Elizabeth Jury, Jaanam Gopalakrishnan, Rufei Lu, Christophe Richez, Fariborz Mobarrez


11:00 AM

12:30 PM

6W029 ACR Abstract: Spondyloarthropathies & Psoriatic Arthritis–Clinical & Treatment V (2968-2973)MODERATORS: Lianne S. Gensler, Denis Poddubnyy

SPEAKERS: Ruth Stoklund Thomsen, Mark C. Genovese, Robert B.M. Landewé, Andreas Kerschbaumer, Anthony So, Michaela Koehm


11:00 AM

12:30 PM

6W030 ACR Abstract: Systemic Sclerosis, Fibrosing Syns & Raynaud's–Clinical & THR III (2980-2985)MODERATORS: Tatiana Sofia Rodriguez-Reyna, Michael York

SPEAKERS: Anna-Maria Hoffmann-Vold, Dinesh Khanna, Duncan F. Moore, Mike Oliver Becker, Gianluca Bagnato


11:00 AM

12:30 PM

6W031 ACR: Global Rheumatology: Bridging the GapsMODERATORS: Fredrica Smith, Aman Sharma

SPEAKERS: E Michael Lewiecki, Paul S. Pottinger, Jennifer Barton

1.5 Clinical Practice Educator 31 C

63

STARTTIME

ENDTIME


CMECREDITS


ROOM


11:00 AM

12:30 PM

6W032 ACR: The Mindful Rheumatologist & the Science of StressMODERATORS: Faye Hant, Victoria K. Shanmugam

SPEAKERS: Liselotte Dyrbye, Leonard H. Calabrese, Neda Gould

1.5 Clinical Science Educator, Ethics, Fellows-

in-Training, Patient Safety,

Practice Manager, Tech

Med

11 A

11:00 AM

12:30 PM

6W033 ARHP Abstract: Epidemiology and Public Health (2986-2991)MODERATORS: Susan L. Murphy, Rebecca J. Cleveland

SPEAKERS: Prae Charoenwoodhipong, Louise Murphy, Nancy A. Baker, Patricia Kachur, Na Lu, Meredith Christiansen


1:00 PM

4:00 PM

6W034 Exhibits: Industry-Supported Post Meeting Symposia

0 See page 67or the Annual


symposia.



64

SUNDAY, NOVEMBER 5

Innovation Theater A

10:30 – 11:15 am

Genentech: A Pioneer of Treatments in GCA and GPA & MPAPresented by Genentech

12:30 – 1:15 pm

Practical Perspectives for Managing Treatment of Moderate to Severe Rheumatoid ArthritisPresented by Pfizer, Inc.

2:30 – 3:15 pm

Exploring a Different Psoriatic Arthritis Treatment for Efficacy Across Multiple DomainsPresented by Celgene Corporation

Innovation Theater B

11:30 am – 12:15 pm

From Pathway to Practice: Critical Considerations for Evaluating BiosimilarsPresented by Amgen

1:30 – 2:15 pm

Going Deeper With COSENTYX® (secukinumab) for Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)Presented by Novartis Pharmaceuticals

3:30 – 4:15 pm

Considerations in the Treatment of Postmenopausal Osteoporosis in Women at High Risk for FracturePresented by Radius Health, Inc.

These non-CME-accredited presentations have been planned and will be implemented with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals.

MONDAY, NOVEMBER 6


10:30 – 11:15 am

1 New RA Therapy, 3 Expert PerspectivesPresented by Sanofi Genzyme & Regeneron

12:30 – 1:15 pm

SLE: Navigating a Complex Disease through Understanding the Role of InterferonPresented by AstraZeneca

2:30 – 3:15 pm

Biosimilars for Rheumatologic Diseases: From Promise to PracticePresented by Samsung Bioepis


11:30 am – 12:15 pm

The Role of the JAK-STAT Pathway in Rheumatoid Arthritis (RA)Presented by Lilly USA, LLC

1:30 – 2:15 pm

ORENCIA® (abatacept): Insights From a Head-to-Head StudyPresented by Bristol-Myers Squibb

3:30 – 4:15 pm

Moving the Treatment of Knee Osteoarthritis Forward: Clinical Evidence for SM04690, a Potential First-in-Class Disease-Modifying Wnt Pathway InhibitorPresented by Samumed, LLC

Innovation Theater A & B Located in the Exhibit Hall





65

These non-CME-accredited presentations have been planned and will be implemented with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals.

TUESDAY, NOVEMBER 7


11:30 – 12:15 pm

Now Available: New Information on the Efficacy and Safety of BENLYSTA (belimumab)

Presented by GlaxoSmithKline

1:30 – 2:15 pm

The evolution of Vectra® DA: the impact of age, gender and adiposity on biomarkers and its relevance to clinical practice

Presented by Crescendo Bioscience

Innovation Theater A & B Located in the Exhibit Hall

TUESDAY, NOVEMBER 7


10:30 – 11:15 am

Evidence-Based Approaches for Accelerating Patient Recruitment and Improving Patient Retention for RA

Presented by Covance

12:30 – 1:15 pm

An evidence-based approach for considering a biosimilar in appropriate patients

Presented by Merck



66

Non-CME SymposiaThe non-CME Programs are wholly sponsored and supported by the commercial entities listed. By holding the Programs, the commercial entities have represented that the Programs have been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entities are to observe all guidelines established by federal and state regulatory agencies regarding non-CME educational or promotional presentations throughout the duration of the Program. The content and views expressed during the Program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the Program nor the products discussed and reviewed during the Program.

CME-Accredited SymposiaFor CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit.

SUNDAY, NOVEMBER 5 AT 6:30 pm

What Lies Beneath the Clinical Manifestations of Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA)?

Non-CME Symposium

Hilton San Diego Bayfront, Sapphire CD

Developed and offered by Novartis Pharmaceuticals

SUNDAY, NOVEMBER 5 AT 6:30 pm continued

Giant Cell Arteritis: Overcoming the Limitations of Conventional Agents with Biologic Therapy

CME-Accredited Symposia

Hilton San Diego Bayfront, Sapphire MN

Supported by an educational grant from Genentech, Inc.

TUESDAY, NOVEMBER 7 AT 6:30 pm

A 3D View - Janus Kinase Inhibition as a Novel Approach to Rheumatoid Arthritis: Emerging Data Impacting Our Treatment Paradigms

CME-Accredited Symposia

Hilton San Diego Bayfront, Sapphire AB

Supported by an educational grant from Lilly USA, LLC

WEDNESDAY, NOVEMBER 8 AT 1:00 pm

A Virtual Reality Tour: Diagnostic Strategies, Evolving Treatments, and Individualized Management of Psoriatic Arthritis

CME-Accredited Symposium

Hilton San Diego Bayfront, Indigo 202

Supported by an educational grant from Lilly

Biosimilars in Rheumatoid Arthritis: Current and Emerging Opportunities to Optimize Care


San Diego Convention Center, Room 4

Supported by an educational grant from Boehringer Ingelheim and Teva Pharmaceuticals

INDUSTRY-SUPPORTED SYMPOSIA LISTING





67

WEDNESDAY, NOVEMBER 8 AT 1:00 pm continued

Systemic Lupus Erythematosus: Advancing the Curve for Recognition and Management


San Diego Convention Center, Room 9

Supported by an educational grant from GlaxoSmithKline

SPARTAN-GRAPPA-ASAS Educational Symposium on Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis (PsA)


Hilton San Diego Bayfront, Indigo E

Supported by an educational grant from AbbVie

The Biosimilars Quiz Game: Evaluating the Role of Biosimilars in the Management of Rheumatologic Conditions


Hilton San Diego Bayfront, Indigo A

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Sandoz, Inc., A Novartis Division.

WEDNESDAY, NOVEMBER 8 AT 1:00 pm continued

Rheumatic Immune-related Adverse Events: Multidisciplinary Perspectives on Recognition and Management


Hilton San Diego Bayfront, Indigo 204

Supported by an educational grant from Bristol-Myers Squibb

Evolving Approaches and New Options in the Management of Osteoporosis in the High-Risk Patient


San Diego Convention Center, Room 5B

Supported by an educational grant from Radius Health, Inc.

INDUSTRY-SUPPORTED SYMPOSIA LISTING



68

The ACR and ARHP wish to thank the following organizations for providing support for the 2017 ACR/ARHP Annual Meeting.

AbbVie

Evening with Rheumatology Fellows-in-Training Hall D-G Lobby Banners Convention Center Column Clings Exhibit Hall Networking Lounges

Amgen, Inc.

Evening with Rheumatology Fellows-in-Training Session Tracker Technology Kiosks Hall D-G Lobby Banner Hall C Lobby Banner ARHP Networking Event

Bristol-Myers Squibb Company

Hall D-E Lobby Escalator Rails Exhibit Hall Hanging Aisle Signs

Celgene Corporation

Conference Shuttle Buses

EMD Serono

Green Screen Photos Seating Cubes

Genentech, a Member of the Roche Group

Evening with Rheumatology Fellows-in-Training

Ironwood Pharmaceuticals

Hall G Lobby Escalator Rails

Novartis Pharmaceuticals

Hall A Lobby Clings Hall D-G Lobby Banners Hotel Key Cards Exhibit Hall WiFi Way

Pfizer, Inc.

Exhibit Hall Floor Decals Hall B2 Lobby Stair Risers

Radius Pharma

Hall D-G Lobby Banners Convention Center Column Clings

Sanofi Genzyme and Regeneron Pharmaceuticals

Charging Kiosks

ANNUAL MEETING SUPPORT ACKNOWLEDGEMENTS





69

In addition to the support provided for the 2017 ACR/ARHP Annual Meeting, the ACR, the ARHP, and the Foundation wish to thank the following organizations for providing support for activities and programs throughout the year.

AbbVieCorporate Roundtable, Leadership LevelFellows Education FundState-of-the-Art Clinical SymposiumARHP Fundamentals of RheumatologyAnnual Meeting Industry-Supported Post-Conference Symposium

Amgen, Inc.Corporate Roundtable, Leadership LevelAmgen Fellowship Training AwardsRISE Registry Founding Sponsor Fellows Education FundPediatric Visiting Professorship Program Pediatric Research Award

AstraZenecaCorporate Roundtable, Principal Level

Bristol-Myers Squibb CompanyCorporate Roundtable, Partner LevelFellows Education Fund

Celgene CorporationCorporate Roundtable, Partner LevelWinter Rheumatology SymposiumProgram Directors’ MeetingDivision Directors’ MeetingState-of-the-Art Clinical SymposiumPediatric Rheumatology SymposiumCARE 2017ARHP eBytesMusculoskeletal Ultrasound Course for Rheumatologists

Genentech, a Member of the Roche GroupCorporate Roundtable, Pinnacle LevelAnnual Meeting Corporate Roundtable Symposium

GlaxoSmithKlineCorporate Roundtable, Executive Level Annual Meeting Industry-Supported Post-Conference Symposium

Horizon PharmaProgram Directors’ MeetingDivision Directors’ MeetingState-of-the-Art Clinical SymposiumPediatric Rheumatology SymposiumCARE 2017ARHP eBytesMusculoskeletal Ultrasound Course for Rheumatologists

Janssen Biotech, Inc.Corporate Roundtable, Partner LevelFellows Education Fund

Lilly USA, LLCCorporate Roundtable, Principal LevelWinter Rheumatology SymposiumProgram Directors’ MeetingDivision Directors’ MeetingState-of-the-Art Clinical SymposiumPediatric Rheumatology SymposiumCARE 2017ARHP eBytesMusculoskeletal Ultrasound Course for RheumatologistsAnnual Meeting Corporate Roundtable SymposiumAnnual Meeting Industry-Supported Post-Conference Symposium

Mallinckrodt PharmaceuticalsCorporate Roundtable, Partner LevelProgram Directors’ MeetingDivision Directors’ MeetingState-of-the-Art Clinical SymposiumPediatric Rheumatology SymposiumCARE 2017ARHP eBytesMusculoskeletal Ultrasound Course for Rheumatologists

Novartis PharmaceuticalsCorporate Roundtable, Principal LevelAnnual Meeting Corporate Roundtable Symposium

Pfizer, Inc.Corporate Roundtable, Leadership LevelFellows Education FundState-of-the-Art Clinical Symposium

Regeneron Healthcare SolutionsCorporate Roundtable, Partner LevelState-of-the-Art Clinical SymposiumPediatric Rheumatology SymposiumCARE 2017ARHP eBytesMusculoskeletal Ultrasound Course for Rheumatologists

Sanofi USCorporate Roundtable, Partner LevelState-of-the-Art Clinical SymposiumPediatric Rheumatology SymposiumCARE 2017ARHP eBytesMusculoskeletal Ultrasound Course for Rheumatologists

UCB, Inc.Corporate Roundtable, Principal Level

YEAR-ROUND SUPPORT ACKNOWLEDGEMENTS



70

SUNDAY, NOVEMBER 5

Guided Poster Tours A9:00 – 9:45 am

(301) Rheumatology 360

(302) Fellows Only: How to Navigate the Poster Hall

(303) Epidemiology and Public Health

(304) RA – Small Molecules, Biologics and Gene Therapy

(305) Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment

(306) SLE – Clinical Aspects

Guided Poster Tours B10:15 – 11:00 am

(307) Health Services Research

(308) Imaging of Rheumatic Diseases

(309) RA – Clinical Aspects



(312) Vasculitis

MONDAY, NOVEMBER 6




(315) Pediatric Rheumatology – Clinical Aspects





(319) Osteoarthritis – Clinical Aspects

(320) Patient Outcomes, Preferences, and Attitudes

(321) Reproductive Issues in Rheumatic Disorders



(324) Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics

TUESDAY, NOVEMBER 7



(326) Rheumatology 360 (En Español)


(328) Miscellaneous Rheumatic and Inflammatory Diseases




(331) Measures and Measurement of Healthcare Quality

(332) Metabolic and Crystal Arthropathies

(333) Patient Outcomes, Preferences, and Attitudes



(336) Vasculitis

2017 GUIDED POSTER TOURS



N o t e s

KJob Number: 22191Revision Nm: 1Date: 10/04/17042-52768 P1

Enbrel® (etanercept) Brief SummarySEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

WARNING: SERIOUS INFECTIONS AND MALIGNANCIESSERIOUS INFECTIONSPatients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.Enbrel should be discontinued if a patient develops a serious infection or sepsis.Reported infections include:• Active tuberculosis, including reactivation of latent tuberculosis. Patients

with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use.

• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

• Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.MALIGNANCIESLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel.

INDICATIONS AND USAGERheumatoid ArthritisEnbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone.Polyarticular Juvenile Idiopathic ArthritisEnbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older.Psoriatic ArthritisEnbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate.Ankylosing SpondylitisEnbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).Plaque PsoriasisEnbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.CONTRAINDICATIONSEnbrel should not be administered to patients with sepsis.WARNINGS AND PRECAUTIONSSerious InfectionsPatients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients:• With chronic or recurrent infection;• Who have been exposed to tuberculosis;• With a history of an opportunistic infection;• Who have resided or traveled in areas of endemic tuberculosis or endemic mycoses,

such as histoplasmosis, coccidioidomycosis, or blastomycosis; or• With underlying conditions that may predispose them to infection, such as advanced

or poorly controlled diabetes [see Adverse Reactions].Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel.Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated.TuberculosisCases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel.Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.

Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

Invasive Fungal InfectionsCases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric anti-fungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric anti-fungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of anti-fungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel.

Neurologic ReactionsTreatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barre syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions].MalignanciesLymphomasIn the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months).

Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general U.S. population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity.

Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials.

LeukemiaCases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia.

During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months).

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years.

Other MalignanciesInformation is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies.

For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general U.S. population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown.

Melanoma and Non-Melanoma Skin Cancer (NMSC)Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept.

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of melanoma was 0.043 cases per 100 patient-years.

Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult PsO patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years.

Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel.

Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric PatientsMalignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at ≤ 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.

In clinical trials of 1140 pediatric patients representing 1927.2 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported.Postmarketing UseIn global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported.Patients With Heart FailureTwo clinical trials evaluating the use of Enbrel in the treatment of heart failure were

terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully.

Hematologic ReactionsRare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities.Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy.

Hepatitis B ReactivationReactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-blocking agents, including very rare cases (< 0.01%) with Enbrel, has been reported. In some instances, hepatitis B reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to hepatitis B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients previously infected with HBV and requiring treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti-viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation.

Allergic ReactionsAllergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated.Caution: The following components contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex: the needle cover of the prefilled syringe, the needle cover within the white cap of the SureClick autoinjector, and the needle cover within the purple cap of the Enbrel Mini cartridge.

ImmunizationsLive vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions and Use in Specific Populations].AutoimmunityTreatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated.

ImmunosuppressionTNF mediates inflammation and modulates cellular immune responses. TNF-blocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Warnings and Precautions and Adverse Reactions].Use in Wegener’s Granulomatosis PatientsThe use of Enbrel in patients with Wegener’s granulomatosis receiving immunosuppressive agents is not recommended. In a study of patients with Wegener’s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non-cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions].Use with Anakinra or AbataceptUse of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions].Use in Patients with Moderate to Severe Alcoholic HepatitisIn a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis.

ADVERSE REACTIONSThe following serious adverse reactions are discussed in greater detail in other sections of the labeling:• Serious Infections [see Boxed Warning and Warnings and Precautions]• Neurologic Reactions [see Warnings and Precautions]• Malignancies [see Boxed Warning and Warnings and Precautions]• Patients with Heart Failure [see Warnings and Precautions]• Hematologic Reactions [see Warnings and Precautions]• Hepatitis B Reactivation [see Warnings and Precautions]• Allergic Reactions [see Warnings and Precautions]• Autoimmunity [see Warnings and Precautions]• Immunosuppression [see Warnings and Precautions] Clinical Trials ExperienceAcross clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions.Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice.Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque PsoriasisThe data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months.

N o t e s


Enbrel® (etanercept) Brief SummarySEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

WARNING: SERIOUS INFECTIONS AND MALIGNANCIESSERIOUS INFECTIONSPatients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.Enbrel should be discontinued if a patient develops a serious infection or sepsis.Reported infections include:• Active tuberculosis, including reactivation of latent tuberculosis. Patients

with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use.

• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

• Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.MALIGNANCIESLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel.

INDICATIONS AND USAGERheumatoid ArthritisEnbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone.Polyarticular Juvenile Idiopathic ArthritisEnbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older.Psoriatic ArthritisEnbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate.Ankylosing SpondylitisEnbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).Plaque PsoriasisEnbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.CONTRAINDICATIONSEnbrel should not be administered to patients with sepsis.WARNINGS AND PRECAUTIONSSerious InfectionsPatients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients:• With chronic or recurrent infection;• Who have been exposed to tuberculosis;• With a history of an opportunistic infection;• Who have resided or traveled in areas of endemic tuberculosis or endemic mycoses,

such as histoplasmosis, coccidioidomycosis, or blastomycosis; or• With underlying conditions that may predispose them to infection, such as advanced

or poorly controlled diabetes [see Adverse Reactions].Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel.Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated.TuberculosisCases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel.Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.

Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

Invasive Fungal InfectionsCases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric anti-fungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric anti-fungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of anti-fungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel.

Neurologic ReactionsTreatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barre syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions].MalignanciesLymphomasIn the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months).

Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general U.S. population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity.

Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials.

LeukemiaCases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia.

During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months).

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years.

Other MalignanciesInformation is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies.

For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general U.S. population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown.

Melanoma and Non-Melanoma Skin Cancer (NMSC)Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept.

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of melanoma was 0.043 cases per 100 patient-years.

Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult PsO patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years.

Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel.

Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric PatientsMalignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at ≤ 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.

In clinical trials of 1140 pediatric patients representing 1927.2 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported.Postmarketing UseIn global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported.Patients With Heart FailureTwo clinical trials evaluating the use of Enbrel in the treatment of heart failure were

terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully.

Hematologic ReactionsRare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities.Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy.

Hepatitis B ReactivationReactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-blocking agents, including very rare cases (< 0.01%) with Enbrel, has been reported. In some instances, hepatitis B reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to hepatitis B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients previously infected with HBV and requiring treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti-viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation.

Allergic ReactionsAllergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated.Caution: The following components contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex: the needle cover of the prefilled syringe, the needle cover within the white cap of the SureClick autoinjector, and the needle cover within the purple cap of the Enbrel Mini cartridge.

ImmunizationsLive vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions and Use in Specific Populations].AutoimmunityTreatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated.

ImmunosuppressionTNF mediates inflammation and modulates cellular immune responses. TNF-blocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Warnings and Precautions and Adverse Reactions].Use in Wegener’s Granulomatosis PatientsThe use of Enbrel in patients with Wegener’s granulomatosis receiving immunosuppressive agents is not recommended. In a study of patients with Wegener’s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non-cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions].Use with Anakinra or AbataceptUse of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions].Use in Patients with Moderate to Severe Alcoholic HepatitisIn a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis.

ADVERSE REACTIONSThe following serious adverse reactions are discussed in greater detail in other sections of the labeling:• Serious Infections [see Boxed Warning and Warnings and Precautions]• Neurologic Reactions [see Warnings and Precautions]• Malignancies [see Boxed Warning and Warnings and Precautions]• Patients with Heart Failure [see Warnings and Precautions]• Hematologic Reactions [see Warnings and Precautions]• Hepatitis B Reactivation [see Warnings and Precautions]• Allergic Reactions [see Warnings and Precautions]• Autoimmunity [see Warnings and Precautions]• Immunosuppression [see Warnings and Precautions] Clinical Trials ExperienceAcross clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions.Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice.Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque PsoriasisThe data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months.


In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied.Adverse Reactions in Pediatric PatientsIn general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions, Use in Specific Populations, and Clinical Studies].In a 48-week clinical study in 211 children aged 4 to 17 years with pediatric PsO, the adverse reactions reported were similar to those seen in previous studies in adults with PsO. Long-term safety profile for up to 264 additional weeks was assessed in an open-label extension study and no new safety signals were identified.In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children.InfectionsInfections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents.In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and adult PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza.In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in adult PsO patients, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials.In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the U.S. and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions].The types of infections reported in pediatric patients with PsO and JIA were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae.Injection Site ReactionsIn placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of adult patients and 7% of pediatric patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given.Other Adverse Reactions Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA.

Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials

Placebo Controlleda (Studies I, II, and a

Phase 2 Study)

Active Controlledb (Study III)

Placebo (N = 152)

Enbrelc (N = 349)

MTX (N = 217)

Enbrelc (N = 415)

Reaction Percent of Patients Percent of PatientsInfectiond (total)Upper Respiratory Infectionse

Non-upper Respiratory InfectionsInjection Site ReactionsDiarrheaRashPruritusPyrexiaUrticariaHypersensitivity

3930

15

11

921–1–

5038

21

37

8323––

8670

59

18

16195441

8165

54

43

16135221

a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms.

bStudy duration of 2 years.cAny dose.dIncludes bacterial, viral, and fungal infections.e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis and influenza.

In placebo-controlled adult PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group.Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II.

Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II)

Placebo (N = 359)

Enbrela (N = 876)

Reaction Percent of Patients

Infectionb (total)Non-upper Respiratory InfectionsUpper Respiratory Infectionsc

Injection Site ReactionsDiarrheaRashPruritusUrticariaHypersensitivityPyrexia

2814

17

6

212––1

2712

17

15

31111–

a Includes 25 mg subcutaneous (SC) once weekly (QW), 25 mg SC twice weekly (BIW), 50 mg SC QW, and 50 mg SC BIW doses.

bIncludes bacterial, viral and fungal infections.c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis.

ImmunogenicityAs with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Enbrel in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.ImmunogenicityPatients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel.In adult PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6%–8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown.In pediatric PsO studies, approximately 10% of subjects developed antibodies to etanercept by Week 48 and approximately 16% of subjects developed antibodies to etanercept by Week 264. All of these antibodies were non-neutralizing. However, because of the limitations of the immunogenicity assays, the incidence of binding and neutralizing antibodies may not have been reliably determined.The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay.AutoantibodiesPatients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions].Postmarketing ExperienceAdverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure.

Adverse reactions are listed by body system below:Blood and lymphatic pancytopenia, anemia, leukopenia, neutropenia, system disorders: thrombocytopenia, lymphadenopathy, aplastic

anemia [see Warnings and Precautions]

Cardiac disorders: congestive heart failure [see Warnings and Precautions]Gastrointestinal disorders: inflammatory bowel disease (IBD)General disorders: angioedema, chest painHepatobiliary disorders: autoimmune hepatitis, elevated transaminases,

hepatitis B reactivationImmune disorders: macrophage activation syndrome, systemic vasculitis, sarcoidosisMusculoskeletal and lupus-like syndromeconnective tissue disorders:Neoplasms benign, melanoma and non-melanoma skin cancers,malignant, and unspecified: Merkel cell carcinoma [see Warnings and Precautions]Nervous system disorders: convulsions, multiple sclerosis, demyelination,

optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions]

Ocular disorders: uveitis, scleritisRespiratory, thoracic interstitial lung diseaseand mediastinal disorders:Skin and subcutaneous cutaneous lupus erythematous, cutaneous tissue disorders: vasculitis (including leukocytoclastic vasculitis),

erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar)

Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use.Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD.DRUG INTERACTIONSSpecific drug interaction studies have not been conducted with Enbrel.VaccinesMost PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel.Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions].Immune-Modulating Biologic ProductsIn a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L).In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions].CyclophosphamideThe use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions].

SulfasalazinePatients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown.USE IN SPECIFIC POPULATIONSPregnancyRisk SummaryAvailable studies with use of etanercept during pregnancy do not reliably support an association between etanercept and major birth defects. Clinical data are available from the Organization of Teratology Information Specialists (OTIS) Enbrel Pregnancy Registry in women with rheumatic diseases or psoriasis and a Scandinavian study in pregnant women with chronic inflammatory disease. Both the OTIS Registry and the Scandinavian study showed the proportion of liveborn infants with major birth defects was higher for women exposed to etanercept compared to diseased etanercept unexposed women. However, the lack of pattern of major birth defects is reassuring and differences between exposure groups (eg. disease severity) may have impacted the occurrence of birth defects (see Data). In animal reproduction studies with pregnant rats and rabbits, no fetal harm or malformations were observed with subcutaneous administration of etanercept during the period of organogenesis at doses that achieved systemic exposures 48 to 58 times the exposure in patients treated with 50 mg Enbrel once weekly (see Data).All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the United States, about 2-4% of liveborn babies have a major birth defect and about 15-20% of pregnancies end in miscarriage, regardless of drug exposure.Clinical ConsiderationsFetal/Neonatal adverse reactions The risk of fetal/neonatal adverse reactions with in utero exposure to Enbrel is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to Enbrel in utero [see Use in Specific Populations].DataHuman DataA prospective cohort pregnancy registry conducted by OTIS in the US and Canada between 2000 and 2012 compared the risk of major birth defects in liveborn infants of women with rheumatic diseases or psoriasis exposed to etanercept in the first trimester. The proportion of major birth defects among liveborn infants in the etanercept-exposed (N = 319) and diseased etanercept unexposed cohorts (N = 144) was 9.4% and 3.5%, respectively. The findings showed no statistically significant increased risk of minor birth defects and no pattern of major or minor birth defects.A Scandinavian study compared the risk of major birth defects in liveborn infants of women with chronic inflammatory disease (CID) exposed to TNF-inhibitors during early pregnancy. Women were identified from the Danish (2004-2012) and Swedish (2006-2012) population based health registers. The proportion of major birth defects among liveborn infants in the etanercept-exposed (N=344) and CID etanercept unexposed cohorts (N = 21,549) was 7.0% and 4.7%, respectively.Overall, while both the OTIS Registry and Scandinavian study show a higher proportion of major birth defects in etanercept-exposed patients compared to diseased etanercept unexposed patients, the lack of pattern of birth defects is reassuring and differences between exposure groups (e.g. disease severity) may have impacted the occurrence of birth defects.Three case reports from the literature showed that cord blood levels of etanercept at delivery, in infants born to women administered etanercept during pregnancy, were between 3% and 32% of the maternal serum level.Animal DataIn embryofetal development studies with etanercept administered during the period of organogenesis to pregnant rats from gestation day (GD) 6 through 20 or pregnant rabbits from GD 6 through 18, there was no evidence of fetal malformations or embryotoxicity in rats or rabbits at respective doses that achieved systemic exposures 48 to 58 times the exposure in patients treated with 50 mg Enbrel once weekly (on an AUC basis with maternal subcutaneous doses up to 30 mg/kg/day in rats and 40 mg/kg/day in rabbits). In a peri-and post-natal development study with pregnant rats that received etanercept during organogenesis and the later gestational period from GD 6 through 21, development of pups through post-natal day 4 was unaffected at doses that achieved exposures 48 times the exposure in patients treated with 50 mg Enbrel once weekly (on an AUC basis with maternal subcutaneous doses up to 30 mg/kg/day).LactationRisk SummaryLimited data from published literature show that etanercept is present in low levels in human milk and minimally absorbed by a breastfed infant. No data are available on the effects of etanercept on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Enbrel and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.Pediatric UseEnbrel has been studied in 69 children with moderately to severely active polyarticular JIA aged 2 to 17 years.Enbrel has been studied in 211 pediatric patients with moderate to severe PsO aged 4 to 17 years.Enbrel has not been studied in children < 2 years of age with JIA and < 4 years of age with PsO. For pediatric specific safety information concerning malignancies and inflammatory bowel disease [see Warnings and Precautions and Adverse Reactions].The clinical significance of infant exposure to Enbrel in utero is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to exposed infants. For pediatric specific safety information concerning vaccinations [see Warnings and Precautions and Drug Interactions].Geriatric UseA total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 patients treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO patients is too small to determine whether they respond differently from younger patients. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly.Use in DiabeticsThere have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

Rx Only.This brief summary is based on ENBREL prescribing information v. 58 09/2017

© 2017 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved.

US License Number 1132© 1998 – 2017 Immunex Corporation.

All rights reserved.US Patent Nos. 7,915,225; 5,605,690; Re. 36,755.

For more information please call 1-888-436-2735 or visit www.enbrel.com

PIV58


In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied.Adverse Reactions in Pediatric PatientsIn general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions, Use in Specific Populations, and Clinical Studies].In a 48-week clinical study in 211 children aged 4 to 17 years with pediatric PsO, the adverse reactions reported were similar to those seen in previous studies in adults with PsO. Long-term safety profile for up to 264 additional weeks was assessed in an open-label extension study and no new safety signals were identified.In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children.InfectionsInfections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents.In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and adult PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza.In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in adult PsO patients, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials.In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the U.S. and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions].The types of infections reported in pediatric patients with PsO and JIA were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae.Injection Site ReactionsIn placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of adult patients and 7% of pediatric patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given.Other Adverse Reactions Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA.

Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials

Placebo Controlleda (Studies I, II, and a

Phase 2 Study)

Active Controlledb (Study III)

Placebo (N = 152)

Enbrelc (N = 349)

MTX (N = 217)

Enbrelc (N = 415)

Reaction Percent of Patients Percent of PatientsInfectiond (total)Upper Respiratory Infectionse

Non-upper Respiratory InfectionsInjection Site ReactionsDiarrheaRashPruritusPyrexiaUrticariaHypersensitivity

3930

15

11

921–1–

5038

21

37

8323––

8670

59

18

16195441

8165

54

43

16135221

a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms.

bStudy duration of 2 years.cAny dose.dIncludes bacterial, viral, and fungal infections.e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis and influenza.

In placebo-controlled adult PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group.Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II.

Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II)

Placebo (N = 359)

Enbrela (N = 876)

Reaction Percent of Patients

Infectionb (total)Non-upper Respiratory InfectionsUpper Respiratory Infectionsc

Injection Site ReactionsDiarrheaRashPruritusUrticariaHypersensitivityPyrexia

2814

17

6

212––1

2712

17

15

31111–

a Includes 25 mg subcutaneous (SC) once weekly (QW), 25 mg SC twice weekly (BIW), 50 mg SC QW, and 50 mg SC BIW doses.

bIncludes bacterial, viral and fungal infections.c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis.

ImmunogenicityAs with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Enbrel in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.ImmunogenicityPatients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel.In adult PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6%–8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown.In pediatric PsO studies, approximately 10% of subjects developed antibodies to etanercept by Week 48 and approximately 16% of subjects developed antibodies to etanercept by Week 264. All of these antibodies were non-neutralizing. However, because of the limitations of the immunogenicity assays, the incidence of binding and neutralizing antibodies may not have been reliably determined.The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay.AutoantibodiesPatients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions].Postmarketing ExperienceAdverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure.

Adverse reactions are listed by body system below:Blood and lymphatic pancytopenia, anemia, leukopenia, neutropenia, system disorders: thrombocytopenia, lymphadenopathy, aplastic

anemia [see Warnings and Precautions]

Cardiac disorders: congestive heart failure [see Warnings and Precautions]Gastrointestinal disorders: inflammatory bowel disease (IBD)General disorders: angioedema, chest painHepatobiliary disorders: autoimmune hepatitis, elevated transaminases,

hepatitis B reactivationImmune disorders: macrophage activation syndrome, systemic vasculitis, sarcoidosisMusculoskeletal and lupus-like syndromeconnective tissue disorders:Neoplasms benign, melanoma and non-melanoma skin cancers,malignant, and unspecified: Merkel cell carcinoma [see Warnings and Precautions]Nervous system disorders: convulsions, multiple sclerosis, demyelination,

optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions]

Ocular disorders: uveitis, scleritisRespiratory, thoracic interstitial lung diseaseand mediastinal disorders:Skin and subcutaneous cutaneous lupus erythematous, cutaneous tissue disorders: vasculitis (including leukocytoclastic vasculitis),

erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar)

Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use.Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD.DRUG INTERACTIONSSpecific drug interaction studies have not been conducted with Enbrel.VaccinesMost PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel.Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions].Immune-Modulating Biologic ProductsIn a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L).In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions].CyclophosphamideThe use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions].

SulfasalazinePatients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown.USE IN SPECIFIC POPULATIONSPregnancyRisk SummaryAvailable studies with use of etanercept during pregnancy do not reliably support an association between etanercept and major birth defects. Clinical data are available from the Organization of Teratology Information Specialists (OTIS) Enbrel Pregnancy Registry in women with rheumatic diseases or psoriasis and a Scandinavian study in pregnant women with chronic inflammatory disease. Both the OTIS Registry and the Scandinavian study showed the proportion of liveborn infants with major birth defects was higher for women exposed to etanercept compared to diseased etanercept unexposed women. However, the lack of pattern of major birth defects is reassuring and differences between exposure groups (eg. disease severity) may have impacted the occurrence of birth defects (see Data). In animal reproduction studies with pregnant rats and rabbits, no fetal harm or malformations were observed with subcutaneous administration of etanercept during the period of organogenesis at doses that achieved systemic exposures 48 to 58 times the exposure in patients treated with 50 mg Enbrel once weekly (see Data).All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the United States, about 2-4% of liveborn babies have a major birth defect and about 15-20% of pregnancies end in miscarriage, regardless of drug exposure.Clinical ConsiderationsFetal/Neonatal adverse reactions The risk of fetal/neonatal adverse reactions with in utero exposure to Enbrel is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to Enbrel in utero [see Use in Specific Populations].DataHuman DataA prospective cohort pregnancy registry conducted by OTIS in the US and Canada between 2000 and 2012 compared the risk of major birth defects in liveborn infants of women with rheumatic diseases or psoriasis exposed to etanercept in the first trimester. The proportion of major birth defects among liveborn infants in the etanercept-exposed (N = 319) and diseased etanercept unexposed cohorts (N = 144) was 9.4% and 3.5%, respectively. The findings showed no statistically significant increased risk of minor birth defects and no pattern of major or minor birth defects.A Scandinavian study compared the risk of major birth defects in liveborn infants of women with chronic inflammatory disease (CID) exposed to TNF-inhibitors during early pregnancy. Women were identified from the Danish (2004-2012) and Swedish (2006-2012) population based health registers. The proportion of major birth defects among liveborn infants in the etanercept-exposed (N=344) and CID etanercept unexposed cohorts (N = 21,549) was 7.0% and 4.7%, respectively.Overall, while both the OTIS Registry and Scandinavian study show a higher proportion of major birth defects in etanercept-exposed patients compared to diseased etanercept unexposed patients, the lack of pattern of birth defects is reassuring and differences between exposure groups (e.g. disease severity) may have impacted the occurrence of birth defects.Three case reports from the literature showed that cord blood levels of etanercept at delivery, in infants born to women administered etanercept during pregnancy, were between 3% and 32% of the maternal serum level.Animal DataIn embryofetal development studies with etanercept administered during the period of organogenesis to pregnant rats from gestation day (GD) 6 through 20 or pregnant rabbits from GD 6 through 18, there was no evidence of fetal malformations or embryotoxicity in rats or rabbits at respective doses that achieved systemic exposures 48 to 58 times the exposure in patients treated with 50 mg Enbrel once weekly (on an AUC basis with maternal subcutaneous doses up to 30 mg/kg/day in rats and 40 mg/kg/day in rabbits). In a peri-and post-natal development study with pregnant rats that received etanercept during organogenesis and the later gestational period from GD 6 through 21, development of pups through post-natal day 4 was unaffected at doses that achieved exposures 48 times the exposure in patients treated with 50 mg Enbrel once weekly (on an AUC basis with maternal subcutaneous doses up to 30 mg/kg/day).LactationRisk SummaryLimited data from published literature show that etanercept is present in low levels in human milk and minimally absorbed by a breastfed infant. No data are available on the effects of etanercept on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Enbrel and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.Pediatric UseEnbrel has been studied in 69 children with moderately to severely active polyarticular JIA aged 2 to 17 years.Enbrel has been studied in 211 pediatric patients with moderate to severe PsO aged 4 to 17 years.Enbrel has not been studied in children < 2 years of age with JIA and < 4 years of age with PsO. For pediatric specific safety information concerning malignancies and inflammatory bowel disease [see Warnings and Precautions and Adverse Reactions].The clinical significance of infant exposure to Enbrel in utero is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to exposed infants. For pediatric specific safety information concerning vaccinations [see Warnings and Precautions and Drug Interactions].Geriatric UseA total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 patients treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO patients is too small to determine whether they respond differently from younger patients. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly.Use in DiabeticsThere have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

Rx Only.This brief summary is based on ENBREL prescribing information v. 58 09/2017

© 2017 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved.

US License Number 1132© 1998 – 2017 Immunex Corporation.

All rights reserved.US Patent Nos. 7,915,225; 5,605,690; Re. 36,755.

For more information please call 1-888-436-2735 or visit www.enbrel.com

PIV58

KJob Number: 22191Revision Nm: 0Date: 09/21/17

YMC042-52768 P3

IMPORTANT SAFETY INFORMATION

SERIOUS INFECTIONSPatients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.MALIGNANCIESLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL. In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown. Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population. Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.Pediatric PatientsIn patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.NEUROLOGIC REACTIONSTreatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in

postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.CONGESTIVE HEART FAILURECases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored.HEMATOLOGIC REACTIONSRare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed.HEPATITIS B REACTIVATIONReactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including ENBREL. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ENBREL in these patients.ALLERGIC REACTIONSAllergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.IMMUNIZATIONSLive vaccines should not be administered to patients on ENBREL. Pediatric patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, temporarily discontinue ENBREL and consider prophylactic treatment with Varicella Zoster Immune Globulin.AUTOIMMUNITYAutoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops.WEGENER’S GRANULOMATOSIS PATIENTSThe use of ENBREL in patients with Wegener’s granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended.MODERATE TO SEVERE ALCOHOLIC HEPATITISBased on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis.ADVERSE REACTIONSThe most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.DRUG INTERACTIONSThe use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

Please see Brief Summary of Prescribing Information on the preceding pages.

©2017 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved. USA-ERHM-053959

Learn about ENBREL on the next page.

KJob Number: 22191Revision Nm: 0Date: 09/21/17

YMC042-52768 P4

VISIT

#1201B O O T H

Prescription ENBREL is administered by injection.

INDICATIONSENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without MTX.ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

IMPORTANT SAFETY CONSIDERATIONSENBREL suppresses the immune system and has been associated with serious and sometimes fatal infections, including opportunistic infections and TB. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including ENBREL. In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.Please see additional Important Safety Information and Brief Summary on preceding pages.

Patient care across multiple indications

Moderate to Severe Rheumatoid Arthritis (RA)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Moderate to Severe Juvenile Idiopathic

Arthritis (JIA) in Patients 2 Years and Older

Moderate to Severe Chronic Plaque Psoriasis

(PsO) in Patients 4 Years and Older

Support for your patients in and out of the office

NOW APPROVEDNew Enbrel Mini™ with

AutoTouch™*

STATWISE™ Symptoms and Injection

Tracking Tool

ENBREL Support ™

*Enbrel Mini™ single-dose prefilled cartridge; AutoTouch™ reusable autoinjector.

sessi n - American College of Rheumatology...sessi n 2 0 17 Pre-Meeting Courses: Friday, November 3...

Documents

Transcript of sessi n - American College of Rheumatology...sessi n 2 0 17 Pre-Meeting Courses: Friday, November 3...